Improving the functional properties of Lactobacillus reuteri by Pallin, Anton
  
Improving the functional properties of 
Lactobacillus reuteri 
Anton Pallin 
Faculty of Natural Resources and Agricultural Sciences 
Department of Molecular Sciences 
Uppsala 
  
Doctoral thesis 
Swedish University of Agricultural Sciences 
Uppsala 2018 
  
Acta Universitatis agriculturae Sueciae 
2018:47 
ISSN 1652-6880 
ISBN (print version) 978-91-7760-234-7 
ISBN (electronic version) 978-91-7760-235-4 
© 2018 Anton Pallin, Uppsala 
Print: SLU Service/Repro, Uppsala 2018 
Cover: Lactobacillus reuteri DSM 17938 
(Photo: Massimo Micaroni, University of Gothenburg) 
 
  
Lactobacillus reuteri is one of the most clinically studied probiotic bacteria. It has e.g. 
been shown to reduce the incidence and alleviate infantile colic and acute diarrhoea in 
children aged 3-60 months. The mechanisms of action behind the clinical effects are not 
fully understood, but two possibilities are inhibition of increased intestinal permeability 
(leaky gut) and alleviation of pain perception through inhibition of one of the key 
receptors (TRPV1) involved in visceral pain. The most studied strain of L. reuteri is DSM 
17938, which has demonstrated good effects in clinical studies. 
 To study whether DSM 17938 and other strains could produce bioactive metabolites 
with a possible inhibitory effect against leaky gut syndrome, different varieties of barley 
flour were used as growth substrate. Growth and metabolic activity were analysed for 
different L. reuteri-barley flour combinations, through an overview of the metabolic 
profile and more targeted chemical analyses. Catabolites of tryptophan previously shown 
to be bioactive compounds (e.g. AhR-ligands) were detected. Supernatants from L. 
reuteri-barley flour combinations with high and low concentrations of these catabolites 
were evaluated for possible protective effect against increased permeability in an 
intestinal epithelial cell model. Only a minor protective effect was seen for a few 
supernatants and no correlations were found between content of AhR-ligands and effect 
on leakage. 
In further attempts to improve the clinical effect of L. reuteri, experiments were 
performed to enhance certain functional properties through the use of experimental 
evolution. DSM 17938 has been shown to have flaws in certain properties that might 
contribute to the probiotic efficacy, e.g. freeze-thaw tolerance, bile tolerance and binding 
to intestinal mucus. Through experimental evolution, these properties were improved for 
DSM 17938 and, although genetic differences were only seen in two variants compared 
with the wild type, differences in protein expression were seen for all new variants.  
Evaluation of the new variants in cell culture models showed that they had similar 
effects to wild-type DSM 17938 on inhibition of TRPV1, although in vitro tests using 
intestinal epithelial cells revealed that some of the variants had lost their inhibitory effect 
against increased permeability. Overall, however, the variants retained most of the 
properties seen in vitro for wild-type DSM 17938. 
Keywords: Lactobacillus reuteri, barley, metabolomics, bile tolerance, mucus binding, 
experimental evolution, epithelial permeability, TRPV1, proteomics 
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Abstract 
  
Lactobacillus reuteri är en av de mest kliniskt studerade probiotiska bakterierna. Den har 
bland annat visats sig kunna minska frekvensen av och mildra kolik hos spädbarn och 
akut diarré för barn mellan 3-60 månader. Mekanismerna bakom de kliniska effekterna 
är inte helt förstådda men två av de föreslagna mekanismerna är inhibering av en ökad 
permeabiliteten i tarmen (läckande tarm) och lindring av smärtupplevelsen genom 
inhiberande effekt på en av de huvudsakliga receptorerna (TRPV1) involverade i visceral 
smärta. Den mest studerade stammen av L. reuteri är DSM 17938, som har visat sig ha 
bra effekt i en lång rad kliniska studier.  
För att studera om DSM 17938 och andra stammar av L. reuteri kunde producera 
bioaktiva metaboliter med en möjlig inhiberande effekt mot läckande tarm, användes 
olika sorters kornmjöl som tillväxtsubstrat. Tillväxt och metabolisk aktivitet 
analyserades för olika kombinationer av reuteri och kornmjöl, genom en total översikt av 
metaboliska profiler och mer riktade kemiska analyser. Kataboliter av tryptofan som 
tidigare visat sig vara bioaktiva substanser (t.ex. AhR-ligander) kunde detekteras. 
Supernatanter från kombinationer av reuteri och kornmjöl med hög och låg koncentration 
av dessa kataboliter utvärderades för en möjlig skyddande effekt mot ökad permeabilitet 
i en cellmodel med tarmepitelceller. Bara en mindre skyddande effekt sågs för enstaka 
supernatanter och inga kopplingar hittades mellan innehåll av AhR-ligander och effekt 
mot läckage.  
I ytterligare försök att öka den kliniska effekten av L. reuteri, gjordes försök att 
förbättra vissa funktionella egenskaper genom användning av experimentell evolution. 
DSM 17938 har visat sig ha brister i vissa egenskaper av möjlig betydelse för en 
probiotikans effekt, bland annat frys-tinatolerans, tolerans mot galla och bindning till 
mucus från tarmens. Genom experimentell evolution förbättrades dessa egenskaper för 
DSM 17938 och trots att genetiska skillnader bara hittades i två av de nya varianterna 
jämfört med vildtypen, sågs skillnader i proteinuttrycket för samtliga nya varianter. 
Utvärdering av de nya varianterna i cellmodeller visade att varianterna hade liknande 
effekt jämfört med vildtypen vid inhibering av TRPV1, dock hade vissa varianter tappat 
den inhiberande effekten mot en ökad permeabilitet. Överlag hade dock varianterna 
behållit de flesta av vildtypens egenskaper som testades in vitro. 
Nyckelord: Lactobacillus reuteri, korn, metabolomik, tolerans mot gallsalter, bindning 
till mucus, experimentell evolution, epitelpermeabilitet, TRPV1, proteomik 
Författarens adress: Anton Pallin, SLU, Institutionen för Molekulära Vetenskaper,  
P.O. Box 7015, 750 07 Uppsala, Sverige  
E-post: anton.pallin@slu.se 
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Sammanfattning 
  
To me, myself and Alice 
You’re going to find that many of the truths we cling to depend greatly on our 
own point of view 
Obi-Wan Kenobi 
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ANOVA  Analysis of variance  
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HPLC High-performance liquid 
chromatography 
IBD  Inflammatory bowel disease  
IBS  Irritable bowel disease  
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OPLS-DA Orthogonal projections to latent 
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1.1 For a healthy intestine 
It was long believed that the human body contained around 10 times or even 100 
times as many bacterial cells as human cells (Savage, 1977). This claim is 
contradicted in a recent publication and the numbers are suggested to be closer 
to a 1:1 ratio, with a total mass of approximately 0.2 kg of bacteria in a person 
weighing 70 kg (Sender et al., 2016). The microbiome of an adult human is 
suggested to contain hundreds to thousands of species, with the majority 
belonging to the phyla Bacteroidetes and Firmicutes (Huttenhower et al., 2012; 
Rajilić-Stojanović et al., 2007). Most of these bacteria (around 1013) are found 
in the colon and contribute about half the weight of the colon contents (Sender 
et al., 2016). The reason that the gastrointestinal tract can house such a massive 
number of bacterial cells is because of its sheer size. Measuring a total of 32 m2, 
roughly the size of half a badminton court, this is one of the body’s largest 
external surfaces (Helander & Fändriks, 2014). It has long been believed that the 
human gastrointestinal tract is colonised during and after birth (Mackie et al., 
1999), but this widely accepted hypothesis has been questioned during the past 
decade. Studies suggest that the foetus might not be sterile at all (Walker et al., 
2017; Jiménez et al., 2008). However, this remains to be confirmed, since the 
majority of the findings have been of bacterial DNA, and not viable bacteria 
(Perez-Muñoz et al., 2017). Even if the foetus is not completely sterile, the 
majority of colonisation happens after birth and the composition of the intestinal 
microbiota is believed to be set at an early age (Palmer et al., 2007). The 
intestinal microbial community of an infant has low diversity, low numbers of 
bacteria (bacterial load) and low resilience, and usually consists of bacteria from 
the vagina, skin and breast milk of the mother (Dominguez-Bello et al., 2010). 
Initially, the intestinal environment is oxidative, which allows facultative 
1 Introduction 
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anaerobic bacteria such as proteobacteria (e.g. Escherichia coli) and certain 
lactobacilli to colonise the intestines of infants (Sommer et al., 2017). These 
bacteria are then responsible for their own replacement by decreasing the oxygen 
concentration, which in turn allows anaerobic bacteria such as those belonging 
to the phyla Bacteroidetes, Actinobacteria and Firmicutes to colonise (Sommer 
et al., 2017). This results in a fluctuating microbiota during early life, but over 
the course of the first three years of life the microbial diversity increases and a 
more stable microbial community is established, and in turn a more resilient 
microbiota (Yatsunenko et al., 2012; Koenig et al., 2011). The microbiota is then 
relatively stable throughout the life time of healthy individuals (Rajilić-
Stojanović et al., 2013), although certain factors can influence the composition, 
including physiological state, drugs, disease, diet and stress (Sommer et al., 
2017; Lozupone et al., 2012; Mitsuoka, 1992). Having a stable intestinal 
microbiota with a normal composition is considered important to avoid disease, 
and has been studied as far back as the 1950s. For example, Bohnhoff et al. 
(1954, cit. Schrezenmeir & de Vrese, 2001) showed that mice treated with 
antibiotics become more susceptible to Salmonella infections(Schrezenmeir & 
de Vrese, 2001). Similar observations have been made for guinea pigs following 
oral administration of a specific antibiotic, which left the animals more 
susceptible to Vibrio cholerae (Freter, 1955). In older humans, changes in 
microbiota composition and, especially, loss of diversity are associated with 
increased frailty and reduced cognitive performance (O’Toole & Jeffery, 2015). 
This loss of microbial diversity and the health decline could be correlated with 
a less diverse diet (Claesson et al., 2012). 
A stable microbiome does not just contribute to defence against pathogenic 
microorganisms, since changes or disruptions in the composition of the 
microbiome are also correlated with several different diseases and syndromes. 
Reports of observed changes in microbiome composition in different diseases 
are continually emerging. For example, differences in microbiome composition 
compared with healthy subjects have been observed in people with obesity, 
circulatory disease, inflammatory bowel disease and autism (Tomova et al., 
2015; Lepage et al., 2011; Furet et al., 2010; Qin et al., 2010; Turnbaugh et al., 
2009; Finegold, 2008; Holmes et al., 2008; Marchesi et al., 2007; Turnbaugh et 
al., 2006). Moreover, an influence of the intestinal microbiome on drug 
metabolism and toxicity, dietary calorific bioavailability and recovery after 
surgery has been reported (Kinross et al., 2010; Clayton et al., 2006; Hooper & 
Gordon, 2001). A physiological effect resulting from disruption of the stable 
microbiome, or dysbios, is a condition often referred to as ‘leaky gut’ syndrome, 
which has been linked to several different diseases (Frazier et al., 2011; Sartor, 
2008).  
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1.1.1 Leaky gut 
Leaky gut syndrome, or ‘increased intestinal permeability’, describes an 
inability of the intestine to prevent harmful substances or microorganisms from 
entering the internal environment of the body (Bjarnason et al., 1995). The 
intestine consists of a number of different barriers to prevent this from happening 
(Atuma et al., 2001). These barriers can roughly be divided into three types: 
immunological, biochemical and physical elements. The immunological 
elements include antimicrobial peptides (defensins), secretory immunoglobulins 
and cellular immunity (dendritic cells, macrophages, intraepithelial 
lymphocytes, T regulatory cells, lymphocytes and plasma cells). Biochemical 
elements are bile salts, gastric acid, lysozymes etc. Physical elements, the main 
focus in this thesis, include the commensal microbiota, the mucus layer and the 
intestinal epithelium (see Figure 1). The commensal microbiota compete with 
invasive microorganisms by limiting nutrients and attachment spots for possible 
pathogens and/or by the production of antimicrobial substances (see section 1.1 
of this thesis). The mucus layer consists of one or more layers of highly 
glycosylated hydrated gels formed by the mucin (large glycoproteins) produced 
by goblet cells, which are simple columnar epithelial cells scattered around the 
epithelial lining of e.g. the intestinal tract (Atuma et al., 2001). The tight stacking 
of these glycoproteins forms a compact inner layer closest to the epithelial layer 
that is considered to contain far smaller numbers of bacteria (Dicksved et al., 
2012; Johansson et al., 2008; Swidsinski et al., 2007). The outer mucus layer is 
looser because of proteolytic dispersion, and hence contains more intestinal 
microorganisms (Atuma et al., 2001). The epithelial layer in turn consists of two 
barriers (Figure 1). The cell membrane consists of lipids, which prevent water-
soluble substances from passing through (Hollander, 1999). Between each 
epithelial cell there is a second barrier, where the gap between cells, called the 
paracellular space, contain protein complexes that control what can/cannot enter 
this space. These proteins are called tight junction (TJ) proteins. When open, 
they can allow fluids, nutrients and even microorganisms to cross from the 
lumen into the lamina propria of the intestine (Madara & Pappenheimer, 1987). 
Leaky gut occurs when the function of these TJ proteins is disturbed, e.g. during 
certain diseases such as inflammatory bowel disease (Lee, 2015; Krug et al., 
2014). 
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Figure 1. Simplified overview of the structure of the small intestine, showing a) the gastrointestinal 
tract, b) intersection of the small intestine with its folds, c, d) villi and e) individual epithelial cells 
with microvilli. The epithelial layer comprises a single cell layer where the paracellular space is 
sealed by tight junction (TJ) proteins, the function of which is to limit leakage of unwanted 
substances or microorganisms. A leaky gut, or increased intestinal permeability, can be caused by 
disturbed function of TJ proteins, leading to microbes entering the lamina propria. 
Studies in the 1980s examined the correlations between Crohn’s disease and 
coeliac disease, and leaky gut. These studies found that subjects suffering from 
Crohn’s disease had increased intestinal permeability of lactulose, which is a 
non-absorbable disaccharide suggested to be taken up only via e.g. tight 
junctions (Ukabam et al., 1983; Pearson et al., 1982). Similar results were 
obtained for subjects with coeliac disease, with higher permeability of similar-
sized molecules (Ukabam & Cooper, 1984; Bjarnason et al., 1983). The effect 
is reversed by excluding gluten from the diet of the latter subjects, leading to 
normal intestinal permeability (Ukabam & Cooper, 1984). An increase in 
intestinal permeability has also been reported in subjects suffering from other 
gastrointestinal disorders, e.g. patients suffering from diarrhoea-predominant 
irritable bowel syndrome (IBS) (Camilleri et al., 2012). These people have 
higher ratios of lactulose/mannitol in urine samples than healthy controls, 
suggesting the same leakage of molecules through the tight junctions as in 
patients with coeliac and Crohn’s disease. This has been shown in several studies 
on people with IBS, and correlations between increased permeability and 
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abdominal pain have been reported in some of these studies (Zhou et al., 2009; 
Dunlop et al., 2006; Spiller et al., 2000). However, those studies also suggest 
connections between other disorders and diseases, including food allergies, 
asthma and some allergic skin conditions, and leaky gut. 
Understanding these connections and knowing how to measure intestinal 
permeability could be paramount in the development of preventative measures 
and early detection of these diseases and disorders. Protection against leaky gut 
could prevent people suffering from painful and bothersome disorders. 
Probiotics have been suggested as a possible treatment and the role of probiotics 
in decreasing intestinal permeability has been evaluated in a number of studies. 
For example, giving probiotic supplements (Lactobacillus rhamnosus 19070-2 
and L. reuteri DSM 12246) to children with severe to moderate dermatitis has 
been shown to decrease the gastrointestinal symptoms (diarrhoea and abdominal 
pain) and intestinal permeability (lactulose/mannitol test) compared with a 
placebo (Rosenfeldt et al., 2004). Treating children suffering from mild to 
moderately active Crohn’s disease with L. rhamnosus GG is reported to result in 
lower disease scores and lower intestinal permeability (cellobiose/mannitol 
ratio) (Gupta et al., 2000). A protective effect against increased intestinal 
permeability, often seen in pre-term infants, has been observed following 
ingestion of pre-term formula supplemented with Bifidobacterium animalis 
subsp. lactis (Stratiki et al., 2007). Intestinal epithelial cell models are available 
for studying how probiotics prevent leaky gut syndrome. These include e.g. 
IPEC-J2 (primary porcine cell line) and Caco-2 (human carcinoma cell line), 
two cell lines that can form polarised monolayers which express tight junction 
complexes (Kandil et al., 1995; Grasset et al., 1984). Probiotics such as L. 
reuteri have been shown to have a protective effect against increased intestinal 
permeability in IPEC-J2 (Karimi et al., 2018; Liu et al., 2015). These studies 
show a protective effect of L. reuteri on the permeability-disrupting effects of 
enterotoxigenic Escherichia coli (ETEC), with a reduction in transepithelial 
resistance, leakage of a fluorescent molecule (FITC-dextran, 4kDa) and 
monolayer damage (tight junction openings) caused by ETEC after pre-
treatment with L. reuteri. 
1.2 Probiotics 
The field of probiotics is considered to have started in the beginning of the 
twentieth century, with Elie Metchnikoff. He postulated that alteration of the 
intestinal microbial balance could have health implications. Those observations 
led to his hypothesis that consumption of yoghurt containing host-friendly 
bacteria could decrease toxin-producing bacteria in the intestine and increase the 
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longevity of the host (Schrezenmeir & de Vrese, 2001). Metchnikoff also 
introduced the concept of probiotic bacteria, by combining the Latin word “pro” 
meaning “for” and the Greek word “bios” meaning “life”. The actual term 
probiotics was coined in 1953 by a scientist named Werner Kollath, referring to 
active substances promoting health (Kollath, 1953). The term was later refined 
to describe growth-promoting factors produced by microorganisms (Lilly & 
Stillwell, 1965). However, the definition mostly used today is: “Probiotics are 
live microorganisms, which when administered in adequate amounts confer a 
health benefit to the host”. This definition was first established by the World 
Health Organisation (WHO) and the Food and Agriculture Organization of the 
United Nations (FAO) in 2001. 
Certain criteria are usually considered important when developing a probiotic 
product (Dunne et al., 2001). First, the microorganism should be host-specific, 
meaning that it should come from the same species as the intended target group, 
i.e. human microorganisms for human probiotic products and canine 
microorganisms for dogs. Second, the probiotic should be able to survive 
passage through the gastrointestinal tract to reach the intended area of action. 
This means that it should be able to survive the pancreatic enzymes, acids and 
bile challenges that it will encounter from the mouth down to the small intestine 
or large intestine. Third, in order to establish (at least temporarily) in the 
intestinal microbial community, it is important for microorganisms to be able to 
adhere to the different mucosal layers of the intestinal lining. This could also be 
an important attribute for immunomodulation, pathogen exclusion and enhanced 
healing of damaged mucosa. Fourth, for pathogen exclusion, but also for 
persistence, production of anti-microbial substances is a desirable characteristic 
for probiotic candidates. Fifth, other more technical properties can be important, 
especially for production on an industrial scale. These include genetic stability, 
lyophilisation tolerance and stability over time (shelf life), good and fast growth, 
and oxygen tolerance. Last but not least, the probiotic candidate obviously needs 
to have a documented beneficial health effect and no or minor side-effects. 
1.2.1 Health effects of probiotics 
The suggested health effects of probiotics are many, including positive effects 
on gut health, oral health, reduction of allergic reactions, boosting of the immune 
system and effects against certain psychological disorders. These suggested 
health effects can be divided into well-documented outcomes with good 
evidence according to meta-analyses, and health effects with low evidence 
where no meta-analyses have been performed or where meta-analyses have 
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failed to find enough evidence for the suggested effect. Examples of health 
effects from probiotic intake supported by good evidence include: 
 
 Reduction in colic symptoms in breastfed infants (Schreck Bird et al., 
2017; Sung et al., 2017) 
 Prevention of severe necrotising enterocolitis, late-onset sepsis and all-
cause mortality in very low birth weight infants (Athalye-Jape et al., 
2018; Dermyshi et al., 2017) 
 Enhancing efficacy of Helicobacter pylori eradication treatment and 
decreasing side-effects (Wang et al., 2017; Tong et al., 2007) 
 Prevention of antibiotic-associated diarrhoea (Blaabjerg et al., 2017; Shen 
et al., 2017) 
 Increased stool frequency and decreased intestinal transit time (Huang & 
Hu, 2017; Miller et al., 2017) 
 Relieving symptoms of irritable bowel syndrome (Yuan et al., 2017; 
Ortiz-Lucas et al., 2013) 
 
Examples of health effects for which further evidence is needed include: 
 
 Reduction in allergic symptoms or prevalence of allergy in infants 
(Cuello-Garcia et al., 2015; Zajac et al., 2015) 
 Treatment of subclinical psychological symptoms, including depression 
and anxiety (Huang et al., 2017; McKean et al., 2017; Huang et al., 2016) 
 Managing caries and periodontitis (Gruner et al., 2016; Martin‐Cabezas 
et al., 2016) 
 
An review article published in 2014 lists at least 25 different species of 
bacteria and yeast with demonstrated probiotic effects (Fijan, 2014). These 
species belong to many different genera, including Bacillus, Enterococcus, 
Escherichia, Lactococcus, Leuconostoc, Pediococcus, Saccharomyces and 
Streptococcus. However, the most frequently used and most well-studied species 
belong to the genera Lactobacillus and Bifidobacterium (Fijan, 2014). Among 
the genus Lactobacillus, one of the most studied species is Lactobacillus reuteri. 
1.2.2 Lactobacillus reuteri 
Lactobacillus reuteri was first isolated in 1962 by microbiologist Gerhard 
Reuter. He noticed differences between L. reuteri and Lactobacillus fermentum, 
but still classified L. reuteri as L. fermentum biotype II. It was not until 1980 that 
Otto Kandler and his group described it as a separate species, and named it after 
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Reuter who first isolated it (Kandler et al., 1980). Lactobacillus reuteri is a 
gastrointestinal tract-associated bacteria and can be found in a wide variety of 
animal hosts, including poultry, pigs, dogs, wolves, rodents etc. (Walter et al., 
2011; Hammes & Hertel, 2006). Before the modern Westernised lifestyle and 
diet had its detrimental effects on the microbiome of humans, L. reuteri is 
believed to have been present in the gastrointestinal tract of the majority of 
human populations. Back in the 1960s and 1970s, it was regularly detected in 
the intestine and was considered to be one of the dominant Lactobacillus species 
(Walter et al., 2011). By 1993, however, a study reported that L. reuteri was only 
detected in 4% of study subjects (Molin et al., 1993). A study from 2015, 
comparing people from non-industrialised areas in Papua New Guinea and 
people from the United States, revealed that the microbial diversity was 
significantly higher in the former group.  One of the species that was most 
affected was L. reuteri, which was present in all the subjects from Papua New 
Guinea, but was mostly absent in people from the United States (Martínez et al., 
2015). 
The only environment outside the body of humans and other warm-blooded 
animals where L. reuteri has been isolated is in high-temperature sourdoughs. 
However, these isolates are most likely to be faecal contaminants of rodent 
origin (Su et al., 2012). Adapting to different conditions by functional and 
sometimes host-specific properties has made it possible for L. reuteri to exist in 
many different animals. The differences in phenotypes seen between strains 
include an ability to adhere to mucus or epithelial cells (sometimes host-specific 
binding) and the production of certain enzymes (such as urease) or anti-
microbial substances (e.g. reuterin) (Mora & Arioli, 2014; Walter et al., 2011; 
MacKenzie et al., 2010). Lactobacillus reuteri belongs to the group of host-
adapted lactobacilli, according to a recent review article presenting an updated 
core phylogenomic tree (Duar et al., 2017). That article divides lactobacilli into 
three groups (free-living, host-adapted and nomadic bacteria) based on the 
isolation source, frequency of isolation, metabolic capabilities, growth 
temperature and ability to withstand environmental stressors present in given 
habitats. The host-adapted lactobacilli usually have a smaller genome size, have 
more specialised properties and lack the metabolic flexibility seen in nomadic 
lactobacilli (Duar et al., 2017). 
Like most other lactobacilli, L. reuteri has high requirements as regards 
nutrient supply and needs easily fermentable sugar, amino acids, vitamins and 
nucleotides in order to grow. If all those requirements are fulfilled, it has a 
duplication time of less than one hour (Gerez et al., 2008). Carbohydrates are 
fermented using the phosphoketolase pathway to form lactic acid, acetic acid, 
ethanol and carbon dioxide. Since this pathway has a low energetic yield, L. 
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reuteri makes use of external electron acceptors, including fructose, glycerol, 
pyruvate, citrate, nitrate and oxygen, to improve this (Årsköld et al., 2008). 
Despite being a demanding bacterial species, it has been shown to be resilient to 
environments with both low pH and the presence of bile salts (Whitehead et al., 
2008; Jacobsen et al., 1999). As mentioned previously, these could be important 
characteristics for a probiotic strain. Some strains of L. reuteri also have the 
ability to produce antimicrobial substances. For example, lactic and acetic acid, 
which L. reuteri, and other lactic acid bacteria, produce during degradation of 
carbohydrates, have been shown to inhibit many microbes, especially Gram-
negative bacteria (In et al., 2013; Alakomi et al., 2000). Another anti-microbial 
substance produced by certain strains of L. reuteri, including strains of dog, 
human, pig and poultry origin (Walter et al., 2011), is 3-
hydroxypropionaldehyde (3-HPA) (reuterin) (Spinler et al., 2014). During 
utilisation of glycerol, these strains can produce this low molecular weight, 
water-soluble, non-proteinaceous and neutral end-product (Spinler et al., 2008). 
Reuterin is formed during anaerobic growth by dehydration of glycerol, and L. 
reuteri can then reduce reuterin to 1,3-propanediol, to regenerate NAD+ from 
NADH to enhance its growth (Schaefer et al., 2010). It can be accumulated by 
L. reuteri and excreted under certain conditions, e.g. the presence of other 
bacteria such as Escherichia, Salmonella, Shigella, Proteus, Staphylococcus, 
Clostridium and Pseudomonas has been shown to stimulate L. reuteri to convert 
glycerol into reuterin (Schaefer et al., 2010; Chung et al., 1989). The production 
of reuterin possibly gives L. reuteri a competitive advantage in the 
gastrointestinal tract (Cleusix et al., 2007). It has also been shown to inhibit 
growth of Gram-negative and Gram-positive bacteria, fungi, protozoa and even 
viruses (Walter et al., 2011; Schaefer et al., 2010; Jacobsen et al., 1999; 
Axelsson et al., 1989). 
In addition to reuterin, the production of yet another antimicrobial substance, 
named reutericyclin, has been observed in some strains, so far exclusively in 
strains of sourdough origin (Zheng et al., 2015). It is also a low molecular weight 
substance, but is a tetramic acid, and does not seem to affect as many different 
microorganisms as reuterin. Against Gram-positive bacteria it has been shown 
to be both bacteriostatic and bactericidal, but against Gram-negative bacteria it 
is ineffective due to the barrier properties of the outer membrane (Gänzle et al., 
2000).  
Lactobacillus reuteri is one of the most clinically studied probiotic species, 
with many studies showing probiotic effects of some strains. Most of the studies 
showing strong clinically proven effects are on children and/or infants. Strain 
DSM 17938 has been shown to work in both therapeutic and preventive settings 
against acute diarrhoea in children between the ages of 3 and 60 months 
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(Urbańska et al., 2016; Gutierrez-Castrellon et al., 2014; Weizman et al., 2005). 
Supplementation of the diet with strain DSM 17938 can also alleviate 
gastrointestinal tract symptoms (constipation and regurgitation) and improve 
colicky symptoms (reduce crying time) in breastfed infants (Sung et al., 2017; 
Indrio et al., 2014; Savino et al., 2010). The risk of developing eczema can also 
be lowered by treating infants with different strains belonging to 
Bifidobacterium and Lactobacillus, one of the species being L. reuteri (Zuccotti 
et al., 2015). Children with ulcerative colitis might also benefit from taking L. 
reuteri, although further studies are needed before an effect can be claimed 
(Oliva et al., 2012). While most of the beneficial effects are seen in infants and 
young children, positive health effects have also been shown in adults. For 
example, in patients suffering from Helicobacter pylori infections, L. reuteri has 
been shown to reduce the overall occurrence of dyspeptic symptoms, abnormal 
defecation and flatulence compared with people receiving a placebo (Francavilla 
et al., 2014; Francavilla et al., 2008). Several studies have also examined the 
effect of L. reuteri on visceral pain. Studies performed using an array of cell 
models and mice models, as well as clinical studies on children, have all shown 
the potential of L. reuteri to inhibit visceral pain (Weizman et al., 2016; Perez‐
Burgos et al., 2015; Kamiya et al., 2006).  
Besides having an effect on a number of symptoms of different diseases and 
syndromes, a rodent L. reuteri strain (R2LC) has been shown to reduce transport 
of live bacteria from the intestinal lumen to the bloodstream (Wang et al., 1995). 
This transport pathway, known as bacterial translocation, is a strategy used by 
pathogenic bacteria, but also by members of the commensal intestinal 
microbiota, when the host is left more exposed than usual, e.g. during stressful 
conditions such as starvation, trauma etc. (Balzan et al., 2007; Berg, 1995). 
Lactobacillus reuteri has also been shown to have a positive effect on 
maintaining intestinal mucosal integrity (Adawi et al., 1997). In addition, an 
effect on gut motility has been suggested as a possible mode of action for L. 
reuteri, e.g. strain DSM 17938 has been shown to lower jejunal velocity and 
increase colon velocity in studies using an ex vivo model (Wu et al., 2013). This 
could explain the positive effect of DSM 17938 against chronic constipation 
seen in a study on children (Coccorullo et al., 2010). 
1.3 Probiotic characteristics 
Previously, it was believed that a bacterial strain should fulfil certain criteria to 
be considered a good probiotic candidate. However, even if this is a good first 
step in screening strains, in the end the only effect that matters is that achieved 
in a clinical setting. This section provides a more detailed picture of the different 
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stresses that bacteria need to overcome and how they have evolved to handle 
different kinds of challenges. It also addresses the topic of production of 
bioactive compounds more extensively. 
1.3.1 Stress tolerance 
Lyophilisation tolerance/survival ability 
Lyophilisation, or freeze-drying, is an important technique for the probiotic 
industry, as it permits longer storage of the bacteria with a slower decrease in 
viable counts, which is important since a high number of viable bacteria could 
affect the efficacy of the probiotic product. The process of lyophilisation 
involves freezing below the glass transition temperature of the formulation, 
followed by drying by sublimation under high vacuum (Jennings, 1999). Drying 
consists of two phases. In the first phase, called primary drying, unbound water 
is removed, while in the second phase the bound water is removed (Jennings, 
1999). Removal of cellular water is needed to preserve the bacteria and 
lyophilisation is considered a gentle method for achieving this (Meng et al., 
2008). However, this process can have a detrimental effect on the bacteria if 
carried out improperly, resulting in damage to the cell wall and membrane 
constituents and leading to cell death (Carvalho et al., 2004). To avoid damage 
to the cells, it is important to have a good cryoprotectant and lyoprotectant in the 
drying medium. Commonly used cryoprotectants and lyoprotectants include e.g. 
skim milk powder, whey protein, trehalose, glycerol, glucose, sucrose, lactose 
and polymers such as dextran (Meng et al., 2008). On addition to the 
formulation, these substances form a protective matrix around the cells, which 
protects them from different kinds of harmful stresses during the process of 
freezing and drying (Wessman et al., 2013). Addition of fermentable sugars to 
the growth medium could also have protective effects on the bacteria, as 
converting these sugars into e.g. mannitol, exopolysaccharides etc. could 
improve the viability during drying (Santivarangkna et al., 2008). 
Supplementation with non-fermentable sugars could also help the cells during 
the drying phase (Santivarangkna et al., 2008). These sugars exert a 
hyperosmotic stress on the bacterial cells during cultivation and, by 
accumulation of compatible solutes, the bacteria could be better equipped to 
resist the osmotic stress during the drying process. These accumulated solutes 
could better help to keep proteins and membranes hydrated (Santivarangkna et 
al., 2008).  
Studies examining the effect of different cryoprotectants on the survival 
ability of L. reuteri CICC6226 after lyophilisation have found that trehalose and 
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skim milk are the best, closely followed by sucrose (Li et al., 2011). A study 
performed on L. reuteri DPC16 also found sucrose to be one of the better 
cryoprotectants (Chen et al., 2011). Tolerance to repeated cycles of freezing and 
thawing is suggested to correlate with an increase in stability and/or survival 
ability of L. reuteri after lyophilisation (Garcia et al., unpublished). The most 
used method for evaluating viable counts after lyophilisation is quantification of 
colony-forming units (CFU) by plate methods. Because of its drawback with 
long incubation times of plates of 24-72 hours or more, other methods are being 
developed for more rapid testing of viability. These methods include e.g. 
fluorescent techniques like flow cytometry to detect live, dead and damaged cells 
by staining with different fluorescent probes (Rault et al., 2007), isothermal 
calorimetry which measures the heat produced by metabolising bacteria (Garcia 
et al., 2017), and real-time quantitative polymerase chain reaction (qPCR) in 
combination with DNA-binding dyes to detect both live cells and total cell 
counts (Shao et al., 2016). 
Tolerance to low pH 
The first challenge after ingestion of a probiotic product is the transport through 
the stomach. Located in the corpus of the stomach are highly specialised cells 
called parietal cells (Martinsen et al., 2005). These cells secrete hydrochloric 
acid (HCl), which causes an increase in the concentration of H+ ions and a drastic 
drop in pH. The pH in the human stomach, as in that of many other omnivores, 
is around pH 3, but the pH mainly depends on how much protein is consumed. 
Carnivores usually have a lower pH, since the secretion of pepsinogen and the 
activity of proteases require a low pH (Beasley et al., 2015). Another function 
of the gastric juice is inactivation of pathogenic microorganisms. Studies have 
shown a bactericidal effect of pH lower than 4, with the potential to kill bacteria 
within 15 minutes (C. et al., 2005). However, more recent studies have 
speculated that low stomach pH may be a double-edged sword, by also damaging 
the chances of re-colonisation by beneficial microbes that might need to be re-
introduced (Beasley et al., 2015). Bacteria are differently affected by low pH, 
e.g. Gram-negative bacteria are believed to have a lower resistance because of 
the inability of their outer membrane to act as a barrier against proton movement 
(Lund et al., 2014). Gram-negative and Gram-positive bacteria have been shown 
to use different mechanisms for surviving exposure to low pH. Species 
belonging to the genus Lactobacillus, like many other organisms, use a 
sophisticated molecular machinery located in the plasma membrane called F1F0-
ATPase (van de Guchte et al., 2002). Protons can either be used to synthesise  
ATP or be expulsed out of the cells using the energy provided during ATP 
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hydrolysis (van de Guchte et al., 2002). In lactic acid bacteria it is mainly the 
latter that is used to maintain the ∆pH (Nannen & Hutkins, 1991). 
Bile acid tolerance 
After surviving the acidic environment of the stomach, the next set of hurdles 
the bacteria need to overcome are the membrane-dissolving bile salts. These are 
formed in the hepatocytes of the liver from cholesterol by a multi-enzyme 
process (Hofmann, 1999). The insoluble, uncharged cholesterol is converted to 
a bile acid molecule, which when ionised becomes an amphipathic, membrane-
dissolving and water-soluble detergent. When the bile salts have been 
synthesised from cholesterol and before they are secreted, they are conjugated 
with either glycine or taurine. This changes them from being weakly acidic to 
strongly acidic (Hofmann, 1999). Bile acids promote dietary lipid absorption in 
the small intestine. By solubilising dietary lipids and their digestion products in 
the form of mixed micelles, they can diffuse through the unstirred layer at an 
accelerated pace. If they are not in micellar form, the fat-soluble vitamins such 
as vitamin A, D, E and K are not absorbed (Hofmann, 1999). Another purpose 
of bile salt synthesis is elimination of cholesterol (Dikkers & Tietge, 2010). The 
cholesterol can be eliminated via the faecal route, by converting some of it to 
bile acids and then through micellar solubilisation of cholesterol in bile, enable 
cholesterol to move from the hepatocyte to the intestinal lumen.  
Since bile salts are membrane-dissolving, they are also antimicrobial (Begley 
et al., 2006). However, certain microbial species have the ability to hydrolyse 
bile salts entering the intestinal lumen, a process which mainly takes place in the 
anaerobic conditions of the colon (Begley et al., 2006). Cytoplasmic bile salt 
hydrolases (BSH), mainly present in Gram-positive strains, can convert bile salts 
by deconjugation (Begley et al., 2006). They hydrolyse the amide bond and 
liberate the glycine/taurine moiety from the steroid core, resulting in 
unconjugated or deconjugated bile acids. Bile salt hydrolases are present in 
species belonging to e.g. the genera Lactobacillus, Bifidobacterium, 
Enterococcus, Clostridium and Bacteroides (Begley et al., 2006; Tanaka et al., 
1999). Their main purpose in bacteria having this activity is believed to be for 
bile detoxification, which allows them to be more persistent in the 
gastrointestinal tract (Dussurget et al., 2002; De Smet et al., 1995). However, 
BSH may also play a nutritional role, and can lead to membrane alterations by 
facilitating incorporation of cholesterol or bile into the membrane (Begley et al., 
2006; Taranto et al., 1997; Tannock et al., 1989), which could make the bacteria 
more resistant to bile, intestinal defensins, lysozymes etc. 
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1.3.2 Mucus binding 
After surviving passage through the stomach and the first part of the small 
intestine, there is a new challenge for the probiotic bacteria. In order for a 
bacterium to persist in the intestine long enough to exert an effect, it must be 
able to bind to the mucosal lining of the intestinal cell layer. As mentioned 
(section 1.1.1 of this thesis), the intestinal layer consists of one or several layers 
of glycoproteins, forming a continuous gel matrix that is bound to the intestinal 
epithelia. The main function of this barrier is to protect the host from harmful 
antigens and microorganisms entering through the epithelial layer, but also to 
promote the transport of food and waste downwards through the gastrointestinal 
tract. The thickness of the mucus layer in the human intestinal tract varies from 
30 to 300 µm, being thinnest in the small intestine and progressively increasing 
down the intestinal tract to be thickest in the rectum (Matsuo et al., 1997). 
As mentioned (section 1.1.1), the glycoproteins or mucins are produced by 
specialised cells in the epithelial layer called goblet cells. When the mucins 
produced by these unicellular cells polymerise, they form a matrix that gives 
protection from pathogens, enzymes, toxins, dehydration and abrasion (Van 
Tassell & Miller, 2011). Mucins are constantly being produced, since the mucus 
layer is subjected to erosion by luminal particular matter and by intestinal 
peristalsis. The secretion of mucin can be increased due to a number of different 
factors, including luminal acid, neuro- and inflammatory mediators, hormone-
like lipids called prostaglandins (Akiba et al., 2000) and by the presence of 
bacteria through the release of so-called effectors (Sicard et al., 2017). The 
mucins can either be translocated to the membrane surface or secreted into the 
mucus matrix. The ability of lactobacilli to adhere to mucus varies greatly among 
species and strains (Rinkinen et al., 2003; Kirjavainen et al., 1998). The binding 
to the mucus layer can involve e.g. large surface proteins with highly repetitive 
structures, though the mechanism is yet to be fully understood. It has been 
suggested that carbohydrate-protein interactions are a possible mechanism 
(Roos & Jonsson, 2002). Studies have managed to describe proteins with mucus-
binding motifs suggested to be conserved in numerous Lactobacillus species 
(Van Tassell & Miller, 2011; Antikainen et al., 2009). Examples of such proteins 
produced by L. reuteri, are Mub (Roos & Jonsson, 2002) and CmbA (Jensen et 
al., 2014). The adhesive properties of these proteins are considered to be due to 
the repeated functional domains within the proteins (Roos & Jonsson, 2002). 
Mub and homologs of these proteins are mainly found in lactic acid bacteria and 
lactobacilli isolated from the intestine of humans and other mammals (Van 
Tassell & Miller, 2011). 
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1.3.3 Production of bioactive compounds 
Bioactive compounds are health-promoting substances which are naturally 
occurring parts of the diet (Kris-Etherton et al., 2002). They can be either non-
essential or essential compounds, but they need to have an established effect on 
health. Bioactive compounds can be isolated nutrients or part of dietary 
supplements, genetically engineered “designer” foods, herbal products or 
processed foods (Biesalski et al., 2009). Although present in many different food 
ingredients, they are not always available for the host. For example, phenolic 
acids found in cereals are mainly bound to arabinoxylans through ester bonds, 
which cannot be hydrolysed by the digestive enzymes found in the human 
intestine (Saura-Calixto, 2010). However, some of these phenolic compounds 
can be released by certain intestinal microorganisms and made accessible to the 
host. For example, during fermentation of barley and oat by species of 
lactobacilli, including L. reuteri, an increase has been seen in levels of 
bioavailability for certain phenolic acids, e.g. caffeic, coumaric, ferulic and 
sinapic acid (Hole et al., 2012). Fermentation of cowpea flour by Lactobacillus 
plantarum has been shown to increase the concentrations of phenolic 
compounds and also the antioxidant activity (Dueñas et al., 2005). The 
concentrations of a major inhibitory neurotransmitter in the mammalian central 
nervous system, gamma-aminobutyric acid (GABA), can also be increased by 
fermentation of different kinds of cereals and sub-cereals by lactobacilli 
(Stromeck et al., 2011; Coda et al., 2010). Production of short-chain fatty acids, 
which are associated with reduced risk of diseases, e.g. cancer, cardiovascular 
disease and inflammatory bowel diseases, has also been shown to occur in 
probiotic bacteria (Floch & Hong-Curtiss, 2002; Jenkins et al., 1999).  
Lactobacillus reuteri is known to be involved in the production or release of 
a number of different bioactive compounds. Cobalamin (vitamin B12), which is 
essential for humans, is produced by L. reuteri since it is needed as a co-factor 
for the enzyme converting glycerol into the anti-microbial substance reuterin 
(Sriramulu et al., 2008; Taranto et al., 2003). Lactobacillus reuteri has also been 
shown to play an important part in the metabolism of tryptophan into highly 
bioactive derivatives, including aryl hydrocarbon receptor (AhR) ligands, 
produced in low carbohydrate, high tryptophan containing medium fermented 
by L. reuteri (Zelante et al., 2013). When interacting with the receptors, these 
ligands promote production of IL-22, which in turn mediates innate antifungal 
resistance and also mucosal protection against inflammation in a mouse model 
(Zelante et al., 2013). Studies have also shown that faeces from humans with 
inflammatory bowel disease (IBD) transferred to mice give lower activation of 
AhR than faeces from healthy humans (Lamas et al., 2016). In a mouse model, 
L. reuteri has also been found to induce a specific class of intestinal T-cells, 
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CD4+CD8αα+ double-positive intraepithelial lymphocytes (DP IELs), which 
are believed to be involved in a number of different immune responses, again 
possibly through production of specific derivatives of tryptophan (Cervantes-
Barragan et al., 2017).   
1.4 Aims of the thesis 
The overall aim of this thesis was to improve the functional properties of 
Lactobacillus reuteri. In Paper I, L. reuteri was cultivated in different types of 
cereal-based substrates, in order to study production of potential bioactive 
compounds. In Papers II and III, the focus was on improving specific functional 
properties connected to improved survival ability and/or increased retention time 
of the bacteria in the intestine, hence improving probiotic-host cell interactions.  
 
Specific objectives of the work were to: 
 
 Isolate and characterise new strains of L. reuteri from cereals (Paper I) 
 Study the growth and general metabolism of isolated strains compared 
with commercial probiotic strains in barley fermentations  (Paper I) 
 Study production of bioactive compounds, with particular focus on 
tryptophan catabolites, during barley fermentation  (section 3.2 of this 
thesis) 
 Study the effect of fermented barley slurries on intestinal permeability in 
a small intestine epithelial cell model (section 3.2 of this thesis) 
 Improve the freeze-thaw tolerance, bile tolerance and mucus binding 
capacity of L. reuteri DSM 17938 through experimental evolution (Paper 
II) 
 Determine the genetic and proteomic changes linked to the changes in 
phenotypes of DSM 17938 (Paper II) 
 Evaluate the stability of the improved functional properties (Paper II) and 
evaluate other possible changes connected to the changed functional 
properties  (Paper III) 
 Study and compare the effect of improved variants in different cell models  
(Paper III)  
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The experiments reported in Paper I included isolation of new strains of L. 
reuteri from cereals, characterisation of said strains and evaluation of growth 
and metabolism of a selected few of the strains in several varieties of whole grain 
barley flour. Strains isolated from cereals were compared with one strain 
previously isolated from cereals and two commercial probiotic strains of L. 
reuteri, as well as one strain of Lactobacillus plantarum (control). 
In Paper II, the experiments focused on improvement of some functional 
properties of L. reuteri DSM 17938, including tolerance to stress inflicted by 
repeated cycles of freeze-thaw and exposure to bile, as well as adhesion capacity 
to mucus. By implementing experimental evolution, subpopulations with 
improved functional properties were isolated and tested for the stability of these 
properties. Genome sequencing and proteomics were performed to identify 
mutations and changes in protein expression. 
Further evaluations of the new variants were performed in Paper III. 
Experiments on other possible phenotypic changes, including growth kinetics, 
hydrophobicity, binding to epithelial cells, and also viability, stability and 
growth kinetics after lyophilisation (freeze-drying), were performed. Finally, the 
potential of the variants to interact with the host was compared with that of the 
wild-type strain in three cell culture models, including two epithelial cell models 
(IPEC-J2 and Caco-2), to study the effect on intestinal permeability, and one 
lymphocyte cell model (Jurkat), to study the antagonistic effect on the TRPV1 
receptor involved in mediating visceral pain. 
Results related to Paper I which need to be repeated, including evaluation of 
the protective effect of fermented barley on intestinal permeability and targeted 
chemical analysis to find possible production of certain bioactive tryptophan 
catabolites, are also reported in this thesis (section 3.2). The origin and name of 
strains and variants used in the thesis can be found in Table 1. 
 
2 Materials and methods 
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Table 1. Genera, species, strain name, variant name and origin of bacteria used in this thesis 
2.1 Culture conditions and methods 
Isolation of new strains from different cereals was achieved by incubating flour-
water mixtures at 37 °C for 24 hours in a water bath without shaking (Paper I). 
The fermented mixtures were serially diluted in PBS (pH 7.4), plated on de Man, 
Rogosa and Sharpe (MRS) agar or Rogosa agar with added vancomycin (50 µg 
mL-1), and incubated anaerobically at 37 °C and 45 °C, respectively. Single 
colonies were picked and transferred to new MRS plates with a numbered grid 
system for subsequent identification and characterisation. 
Pre-cultures for growth and tolerance assays were inoculated in MRS broth 
and incubated at 37 °C overnight. For determining the bacterial densities and 
viable counts, bacteria in different liquid media were serially diluted and plated 
on MRS using the drop plate method (Hoben & Somasegaran, 1982), and 
incubated anaerobically at 37 °C overnight. Counted colonies from several 10-
fold dilutions were multiplied by the dilution factor and averaged, in order to 
determine the number of colony-forming units (CFU) per mL of liquid culture. 
Growth studies were performed using six barley flours with slightly different 
carbohydrate composition (Table 2). Different flours were used to study the 
Genus Species Strain name Variant 
name 
Origin 
Lactobacillus reuteri DSM 17938 WT Plasmid-cured variant of ATCC 55730 
(Rosander et al., 2008) 
 reuteri  FT1 Freeze-thaw tolerance selection isolate 
 reuteri DSM 32847 FT2 Freeze-thaw tolerance selection isolate 
 reuteri  BT5 Bile tolerance selection isolate 
 reuteri DSM 32846 BT6 Bile tolerance selection isolate 
 reuteri DSM 32848 MB4  Mucus binding selection isolate 
 reuteri DSM 32849 MFT3 Combination isolate, originally FT2 
isolated during mucus binding 
selection 
 reuteri ATCC PTA 
6475 
 Breast milk isolate (Spinler et al., 
2008) 
 reuteri LTH 5531  Sourdough isolate (Dal Bello et al., 
2007) 
 reuteri SU12-3  Buckwheat isolate (Pallin et al., 2016) 
 reuteri SU18-3  Millet isolate (Pallin et al., 2016) 
Lactobacillus plantarum 36E  Silage isolate (Johansson et al., 1995) 
Escherichia coli 853/67  (Söderlind et al., 1973) 
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importance of dietary fibre and starch content and composition on the growth 
and metabolism of L. reuteri. For this, 8 g of whole grain flour were mixed with 
21 mL of sterilised deionised water. An overnight culture of each strain was 
added to the mixture and it was incubated in a 37 °C water bath for 24 hours, 
followed by backslopping (transfer of 1 % of the overnight culture to a fresh 
mixture). This procedure was repeated three times before bacteriological and 
chemical analysis. 
Table 2. Differences in nutritional content of the six barley varieties used in Paper I. The 
composition of dietary fibre (DF) and starch was analysed by the Food Science Unit, Department 
of Molecular Sciences, SLU, Uppsala  
  Fructan Arabinoxylan Total DF β-glucan Starch Amylose 
120 NGB 114602 0.9 7.3 18.9 4.4 57.4 27.1 
155 SLU7 3.2 10.7 33 10.5 38.9 27.7 
181 KVL 301 1 11.5 24.3 2.4 44.9 26 
224 SW 28708 2.8 5.7 18.8 6.3 55.4 1.3 
228 KARMOSÉ 2.2 8 22.7 5.1 49.7 40.7 
249 GUSTAV 1.6 6.3 17.9 4.2 59.3 28.4 
2.2 Identification and characterisation of strains 
In Paper I, DNA from the fermented cereals was extracted according to the 
protocol for Gram-positive bacteria in the DNeasy Blood & Tissue Handbook 
(QIAGEN, Hilden, Germany) and analysed for the presence of L. reuteri DNA 
by polymerase chain reaction (PCR) using species-specific primers (L-reu 1 and 
L-reu 4) (Song et al., 2000). Colonies from Rogosa plates with added 
vancomycin were identified by amplification and sequencing of 16S rRNA 
genes using the primers F8M (Edwards et al., 1989) and 926r (Muyzer et al., 
1993). The PCR products were sequenced by Macrogen Inc. and isolates were 
identified at species level by a GenBank DNA search using the BLAST 
algorithm. Isolates identified as L. reuteri were grouped by genomic 
fingerprinting with rep-PCR, using GTG5 primer (Versalovic et al., 1994). 
Strains were further characterised using an assay for the production of reuterin 
(Rosander et al., 2008). The genes encoding glycerol dehydratase, involved in 
reuterin production, and urease were detected by PCR using the primers 
pduCR/pduCF and ureCR/ureCF, respectively (Walter et al., 2011). Multi-locus 
sequence analysis (MLSA) was also employed, using primers for fragments of 
seven housekeeping genes (ddl, dltA, gyrB, leuS, pkt, rpoA and recA) (Oh et al., 
2009). With this procedure, strains can be further characterised by concatenating 
and aligning the genes using Geneious R6, and comparing strains to previously 
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isolated strains of different animal origin. A phylogenetic tree can then be made 
to illustrate the similarities between the strains.  
To determine whether the new variants of DSM 17938 in Paper II were in 
fact DSM 17938 and not contaminants, a PCR using strain-specific primers 
(LR1/1694f and LR1/1694r) (Vestman et al., 2013) was performed. 
2.3 Chemical analyses 
For the metabolic profiling used to group barley-bacteria combinations in Paper 
I, proton nuclear magnetic resonance (1H-NMR) was used. As part of the thesis 
work, a targeted chemical analysis was also performed using quadrupole time of 
flight-liquid chromatography mass spectrometry (QTOF-LCMS). The aim was 
to find tryptophan catabolites produced in the samples studied in Paper I and in 
additional fermentations. 
2.3.1 Proton nuclear magnetic resonance (1H-NMR) 
Triplicate samples from fermented barley slurries with each combination of 
barley-bacteria were centrifuged and sterile-filtered and the pH was adjusted to 
7.4 by dilution in phosphate buffer and addition of NaOH. Buffered samples 
were stored at -20 °C and thawed before analysis with NMR. After addition of 
D2O and an internal reference, the spectra were recorded on a Bruker Avance-
III 600 MHz spectrometer. Peaks in the NMR spectra were identified and 
concentrations were determined using Chenomx NMR suite 7.5 (Chenomx Inc., 
Edmonton, AB, Canada), the Human Metabolome Database (www.hmdb.ca) 
and the Biological Magnetic Resonance Data Bank 
(www.bmrb.wisc.edu/metabolomics/). 
2.3.2 Quadrupole time of flight-liquid chromatography mass 
spectrometry (QTOF-LCMS) 
Slurries from different barley varieties fermented by L. reuteri DSM 17938 and 
ATCC PTA 6475 were centrifuged and the supernatants collected. The 
supernatant was filtered through a 5-µm Acrodisc syringe filter (Pall Life 
Sciences, Portsmouth, UK) followed by a 0.45-µm sterile filter (Filtropur S, 
Sartstedt, Nümbrecht, Germany) and the samples were stored at -20 °C. Thawed 
filtered samples were mixed with methanol at a ratio of 4:6 (sample:methanol) 
to reach a final volume of 500 µL. The mixtures were vortexed for 1 minute 
before being centrifuged at 10 000 x g for 10 min. Then 100 µL of the mixture 
were transferred to a LC-vial and analysed by LC/Q-TOF/MS. Standards for 
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serotonin, melatonin, tryptophan, tryptamine, indole-3-acetate, indole-3-acetic 
acid and kynurenine were also prepared in two concentrations (100 and 1000 
nM). 
The chromatography part of the analysis was performed on an Agilent 1100 
HPLC (Agilent Technologies, Santa Clara, CA), where the aquatic phase A 
consisted of 10 mmol L-1 ammonium formate with 0.1% formic acid (v/v). 
Mobile phase B was made from acetonitrile with 0.1% formic acid (v/v). From 
these phases a gradient was made, the percentage indicating mobile phase B: 0 
min 95%, 0.5 min 95%, 10.5 min 40%, 15 min 40%, 17 min 95% and 32 min 
95%. Extracts were injected onto a Waters Atlantis HILIC Silica column (3 µm, 
2.1 x 150 mm), containing a 10-mm guard column (same composition). The 
column oven was kept at 30 °C and the flow rate over the column was 0.25 mL 
min-1. A time-of-flight mass spectrometer (Bruker maXis impact, Bruker 
Daltonics, Bremen, Germany) was operated in positive ionisation mode with a 
plate offset voltage of 500 V and a capillary voltage of 4kV. For the removal of 
solvents from the samples, nitrogen gas heated to 200 °C was administered at a 
rate of 8 L min-1 with a nebuliser pressure of 2 bar. The digitiser sample rate was 
set at 4 GHz and profile sample spectra were collected at a rate of 1 Hz. Data 
were processed using Compass DataAnalysis 4.1 (Bruker Daltonics, Bremen, 
Germany). Chromatograms were smoothed by one cycle of Gaussian smoothing 
with a width of 2 seconds prior to area calculation. Relative quantification of 
selected metabolites was performed by using the area of extracted ion 
chromatograms based on compound accurate masses (± 0.01 m/z). 
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2.4 Strain improvement 
The experiments on strain improvement (Papers II and III) were performed using 
different assays, including freeze-thaw tolerance, bile tolerance and mucus 
binding capacity. 
2.4.1 Freeze-thaw tolerance 
Lactobacillus reuteri strain DSM 17938 was evaluated for its tolerance to 
repeated cycles of freezing at -50 °C followed by thawing at 37 °C (Paper II). 
After each cycle, samples were taken for viability counts where 10-fold dilution 
series were plated (drop plate method) on MRS agar. Figure 2 illustrates the 
workflow of the assay. After incubation of plates, colonies were picked from 
different time points, re-streaked on MRS plates and frozen as new variants. 
These variants were later tested in the same assay and compared against wild-
type DSM 17938. This method is based on an unpublished assay procedure 
developed by Armando Hernández Garcia, SLU, Uppsala. 
 
Figure 2. Overview of the freeze-thaw tolerance assay. Overnight cultures of Lactobacillus reuteri 
strain DSM 17938 wild type and new variants with improved functional properties were exposed 
to repeated cycles of freezing (-50 °C) and thawing (37 °C). Viable counts were determined by the 
drop plate method after each cycle.  
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2.4.2 Bile tolerance 
Strain DSM 17938 was also evaluated for its tolerance to bile (Paper II). The 
growth medium of an overnight liquid culture was replaced with fresh MRS 
broth containing 0.5% (w/v) porcine bile and incubated at 37 °C for four hours. 
Viable count was determined immediately and then every 30 minutes during 
exposure to bile medium, by plating (drop plate method) 10-fold dilutions of the 
culture (Figure 3). After incubation of the plates, colonies were picked, re-
streaked and later frozen as new variants. Variants were tested using the same 
assay and compared with wild-type DSM 17938. 
 
Figure 3. Overview of the bile tolerance assay. Overnight cultures of Lactobacillus reuteri strain 
DSM 17938 wild type and new variants with improved functional properties were exposed to 0.5% 
(w/v) porcine bile for 240 minutes. Viable counts were determined by the drop plate method and 
analysed every 30 minutes. 
2.4.3 Mucus binding capacity 
The mucus binding capacity of DSM 17938 was evaluated (Paper II) using a 
modified version of an existing method (Roos & Jonsson, 2002) (see Figure 4). 
In brief, microtitre wells were coated with porcine mucus and then washed and 
blocked for unspecific binding. Overnight cultures of DSM 17938, labelled with 
carboxyfluorescein diacetate (cFDA), were added to the wells and incubated at 
37 °C for four hours. After washing of the wells, the number of attached bacteria 
was determined by inverted microscopy, followed by addition of lysis buffer 
(1% sodium dodecyl sulfate in 0.1M NaOH) and analysis of fluorescence 
intensity using a plate reader. Isolation of variants with improved mucus binding 
capacity was achieved by skipping the lysis step and instead adding fresh MRS 
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broth, incubating the wells for 24 hours and plating on MRS agar. Colonies from 
this enrichment procedure were re-streaked and frozen as new variants of wild-
type DSM 17938. 
 
Figure 4. Overview of the mucus binding assay. Microtitre plates were coated with porcine mucus, 
washed and blocked, followed by binding with cFDA-labelled overnight cultures of Lactobacillus 
reuteri strain DSM 17938 wild type and new variants with improved functional properties. 
Unbound bacteria were washed away and binding capacity was determined by inverted microscopy 
and by analysing fluorescence intensity. 
2.4.4 Stability test 
The stability of the improved attributes was tested by performing the same assays 
after 1, 3, 7 and 15 re-inoculations of the variants in MRS broth. The stability of 
a selected few of the new variants from the freeze-thaw tolerance, bile tolerance 
and mucus binding assays was tested. 
2.4.5 Hydrophobicity 
Changes in hydrophobicity of new variants of DSM 17938 were analysed by a 
procedure based on an existing method (Kos et al., 2003). In brief, overnight 
cultures were centrifuged, washed and re-suspended in PBS, and then the optical 
density (OD) measured at 600 nm (OD600) was adjusted to 0.5. To 3 mL of 
culture, 1 mL of xylene was added and the cultures were incubated at room 
temperature. This was followed by vortexing and additional incubation at room 
temperature. The optical density was measured before addition of xylene and 
also in the aqueous phase after xylene addition, in order to determine the 
partitioning of the bacteria and thereby the degree of hydrophobicity. Xylene 
was chosen because of its apolar attributes, which is considered to make it a good 
solvent for evaluating cell surface hydrophobicity (Kos et al., 2003). 
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2.4.6 Analysis of growth kinetics by optical density 
To determine growth kinetics of strains, changes in optical density were 
measured over a time period of 24 hours, using the BioScreen C microbiological 
growth monitoring system (Oy Growth Curves Ab Ltd, Helsinki, Finland). This 
machine automatically measures optical density at different wavelengths, can 
shake the plates and has temperature control. By adding bacteria to each well 
and adjusting the starting optical density, the lag phase, exponential phase and 
stationary phase can be determined during different conditions. In Paper III, this 
method was used to determine differences between wild-type DSM 17938 and 
new variants. Growth kinetics were studied for overnight cultures grown in MRS 
broth and for lyophilised cultures. 
2.4.7 Lyophilisation experiments 
Lyophilisation of wild-type DSM 17938 and the new variants was performed to 
investigate the correlation between increased freeze-thawing tolerance and 
lyophilisation survival ability and stability (Paper III). It was also used to 
investigate whether the survival ability of the other variants were similar to DSM 
17938 or whether any changes had occurred. 
Pre-cultures for each variant and DSM 17938 were performed in 9 mL MRS 
broth incubated at 37 °C overnight. On the following day, the entire volume was 
added to 400 mL of fresh MRS broth and incubated at 37 °C overnight. The 400 
mL cultures were concentrated 20-fold in a 10% sucrose solution to a final 
volume of 20 mL. Aliquots of 1 mL were transferred to vials and these were 
placed in the lyophilising apparatus (Epsilon 2-6D LSCplus, CHRIST, Osterode, 
Germany) and run with for 44 hours under vacuum with a starting temperature 
of -50 °C. Viable counts were determined before and after lyophilisation, by the 
drop plate method. An accelerated stability experiment was performed by 
incubating the lyophilised products at 37 °C and checking viable counts every 
week for 5 weeks.  
2.4.8 Genomics 
Genome sequencing was performed by Jennifer Spinler at Baylor College of 
Medicine, Houston, Texas, USA. To determine whether any changes in the 
genome had occurred during improvement of DSM 17938, whole-genome 
shotgun sequencing was performed on an Illumina MiSeq instrument (Paper II). 
Changes in sequences, including exchanges in base pairs, inserts or deletions, in 
the variants were mapped using the reference genome for DSM 17938.  
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2.4.9 Proteomics 
Changes in protein expression of wild-type DSM 17938 compared with the new 
variants were analysed by Nanoxis Consulting AB (Gothenburg, Sweden). In 
brief, cell pellets containing approximately 9.7 log10 bacterial cells were 
suspended in PBS and gently inverted during a 20-min incubation at room 
temperature. The suspensions were further diluted (10-fold) before being 
transferred to a vial containing glass beads. Bacterial cells were mechanically 
lysed using a TissureLyser (Qiagen) and then frozen until analysis. Sodium 
deoxycholate (SDC) and trypsin were added to the samples, which were 
incubated for eight hours at 37 °C. Neat formic acid was then added, followed 
by centrifugation and collection of supernatant. The samples were labelled using 
tandem mass tag (TMT), and analysed by high-resolution Orbitrap LC-MS/MS. 
The protein sequences predicted from the genome sequence of DSM 17938 were 
used to identify the peptides. 
2.5 Evaluation of host interactions in vitro 
Evaluation of the potential of new probiotic candidate strains often begins with 
simple in vitro models, evaluating tolerance to e.g. low pH, bile, mucus binding. 
This is usually followed by evaluation of host interactions using different cell 
culture models. In this thesis, cell culture models were used to study the effect 
of L. reuteri on intestinal permeability and the interactions with the host’s own 
cells of different types, both epithelial and immune cells (Paper III). One small 
intestinal cell line (IPEC-J2) and one large intestinal cell line (Caco-2) were 
used, in order to study possible similarities in effect on different parts of the 
intestine. 
2.5.1 Intestinal permeability models 
IPEC-J2 
IPEC-J2 is a non-transformed epithelial cell line derived from the mid-jejunum 
of a neonatal piglet (Berschneider, 1989), and is a well-studied model as regards 
cell interactions with pathogenic bacteria and viruses. In Paper III, these cells 
were used to study the protective effect of wild-type DSM 17938 and new 
variants on epithelial permeability. They were also used to study the protective 
effect of the supernatants collected during fermentation of barley in Paper I (the 
results presented are preliminary and not published elsewhere). 
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IPEC-J2 cells were cultivated in flasks with Dulbecco’s modified Eagle’s 
medium/F12 Ham (DMEM/F-12) containing 0.12% sodium bicarbonate, 15 mM 
HEPES, pyridoxine and L-glutamine, with 5% foetal bovine serum (FBS), 
0.5mM sodium pyruvate and antibiotics (penicillin and streptomycin). Cells 
were kept in an incubator at 37 °C in a humidified atmosphere of 5% CO2. Cells 
were maintained by changing the medium every 2-3 days and passaging every 
4-7 days. Experiments were performed on cells seeded on collagen-coated 
membrane filters, kept for 11-12 days with change of medium every other day, 
the last medium change, to antibiotic-free medium, being made 24 hours before 
the experiment. Filters were pre-treated with L. reuteri for six hours, followed 
by six hours of challenge with pathogenic enterotoxigenic Escherichia coli 
(ETEC), known for having a disruptive effect on epithelial integrity. 
Permeability of the seeded monolayer of IPEC-J2 cells was measured in two 
ways, by transepithelial electric resistance (TEER) and by measuring the leakage 
of a high molecular weight fluorescent marker (fluorescein isothiocyanate 
(FITC)-dextran 4kDa) from the apical to the basolateral side. 
Caco-2 
Caco-2 is a human intestinal cell line derived from a human colon 
adenocarcinoma (Fogh et al., 1977). It is mainly used since the cells can develop 
morphological characteristics of normal enterocytes and it is considered a good 
model for intestinal epithelial permeability. 
In Paper III, the Caco-2 cells were used as a complementary cell line for 
studying cell adherence. The protocol for managing the cells was similar to that 
used for the IPEC-J2 cells with one exception that the amount of FBS was kept 
at 10% during cultivation of the cells and during all experiments. 
2.5.2 TRPV1 receptor activation in Jurkat cells 
The transient receptor potential vanilloid subtype 1 (TRPV1) receptor is a non-
selective cation channel in peripheral sensory neurons. It is involved in pain 
sensing and, when activated, leads to an increased influx of calcium ions (Ca2+). 
This channel can also be activated by e.g. increased temperature, acidic or basic 
pH and by endovanilloids such as capsaicin (Pecze et al., 2013). Jurkat cells are 
a transformed human T-cell line obtained from leukaemic cells (Martin et al., 
1981). Studies have confirmed that the plasma membrane of Jurkat cells contains 
TRPV1 (Bertin et al., 2014), which makes this cell line a good model for studies 
on activation of TRPV1. 
Jurkat cells were cultivated in flasks with Roswell Park Memorial Institute 
(RPMI) medium containing 10% FBS, L-glutamine, β-mercaptoethanol and 
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antibiotics (penicillin and streptomycin). The cells were kept in an incubator at 
37 °C in a humidified atmosphere of 5% CO2 and passaged every three days, 
when full confluence was achieved. On the day of the experiment, the medium 
was changed to an antibiotic-free medium, before addition of fluorescent dyes. 
Two dyes were added to study the change in ratio between intra- and 
extracellular Ca2+ levels, i.e. the influx of Ca2+. After one hour of incubation 
under normal incubation conditions, cells were spun down and new medium was 
added along with L. reuteri at different bacteria:Jurkat cell ratios. Following 
another one-hour incubation, the cells were spun down and the medium was 
replaced with PBS containing Ca2+. Capsaicin was added to each tube, followed 
by immediate analysis of ratiometric calcium flux by flow cytometry (BD 
FACSCelesta, BD Bioscience).  
2.6 Statistical analysis 
Different statistical analyses and evaluations were performed depending on the 
type of experiment. In Paper I, one-way and two-way analysis of variance 
(ANOVA) with Student’s t-test was performed using JMP Pro 11 (SAS, Cary, 
NC) to determine differences in the bacterial densities of the strains cultured in 
slurries made from all barley varieties with the two different pre-treatments. 
Principal component analysis (PCA) was used to determine possible correlations 
between specific sugar contents and bacterial densities and a decline in pH (JMP 
Pro 11), and also to find possible groupings from the metabolic profiling of the 
different barley-bacteria combinations using Simca 13 (Umetrics AB, Umeå, 
Sweden) in Paper I. A complex statistical model, Orthogonal Projections to 
Latent Structures Discriminant Analysis (OPLS-DA), was also used to try to 
group these metabolic profiles, with Pareto scaling used for the OPLS-DA 
modelling. Results from the experiments described in Papers II and III were 
analysed by one-way ANOVA followed by post hoc pair-wise comparison using 
Tukey’s t-test. 
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3.1 Growth and metabolism of L. reuteri in whole grain 
barley flour (Paper I) 
Paper I examined whether cultivation of L. reuteri in cereal substrates could 
induce or increase the production of bioactive compounds. Isolation of new 
strains of cereal origin was performed to determine whether ecological 
adaptations existed in such strains, evaluated as differences in growth and 
metabolism compared with strains of other origin. Lactobacillus reuteri has 
previously been shown to be a stable and sometimes dominant member of high 
temperature type II sourdoughs (Corsetti & Settanni, 2007; Gänzle & Vogel, 
2003), even though it is mainly associated with the gastrointestinal tract, vagina, 
breast milk and oral cavity of warm-blooded animals. A possible animal origin 
of the strains isolated from sourdough was first suggested in 2012 (Su et al., 
2012), almost two decades after some of the earliest isolations (Vogel et al., 
1994). In Paper I, new strains of L. reuteri were isolated from three cereals, 
namely barley, buckwheat and millet. It has been shown by Su et al. (2012), 
using MLSA and construction of a phylogenetic tree, that sourdough strains are 
positioned in clades with strains of either rodent or human origin. The strains 
isolated in Paper I were reuterin-negative and urease-positive, characteristics 
usually seen in strains of rodent origin (Frese et al., 2011; Walter et al., 2011). 
When a MLSA was performed on the newly isolated strains in Paper I, as in 
previous studies it revealed that strains of cereal origin cluster together with 
rodent strains, in this case in clade I and III of the phylogenetic tree (Figure 5). 
While the sourdough strains may be of rodent origin, other studies have shown 
that these strains have adapted to this new ecological environment, with an equal 
or even higher competiveness in sourdoughs than strains of rodent origin (Zheng 
et al., 2015). Certain activities also seem to be unique among these sourdough-
adapted strains, such as the presence of a operon of genes connected to the 
3 Results and discussion 
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production of reutericyclin, an antibiotic active against a number of different 
Gram-positive bacteria (Gänzle & Vogel, 2003; Vogel et al., 1999). The 
production of reutericyclin has been suggested to contribute to the 
competiveness of those strains in sourdoughs (Gänzle & Vogel, 2003).  
 
Figure 5. Phylogenetic tree constructed using the concatenated sequences of seven housekeeping 
genes from 84 strains of Lactobacillus reuteri by multi-locus sequence analysis (MLSA). Strains 
isolated (SU3-3, SU7-3, SU12-3, SU17-3 and SU18-3) and used (LTH 5531, DSM 17938 and 
ATCC PTA 6475) in Paper I are marked with strain number instead of colour coding. 
To study possible adaptations of the strains isolated in this thesis work, the 
growth and metabolism of two of the isolated sourdough strains from Paper I 
(SU12-3 and SU18-3) were studied in six different barley flours and compared 
with those of another sourdough strain (LTH 5531) and two strains of human 
origin (DSM 17938 and ATCC PTA 6475). To further push the strains to reveal 
differences, they were cultivated in both untreated and heat-treated whole grain 
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barley flour. The heat treatment of flour was performed to inactivate endogenous 
enzymes and microorganisms which could aid the growth of the strains. The 
results revealed higher bacterial counts in untreated compared with heat-treated 
flours, showing the importance of such endogenous enzymes for the growth of 
L. reuteri in cereal substrates. Only minor differences in bacterial counts were 
seen between the strains in untreated barley flour. In heat-treated flour, DSM 
17938 generally had lower counts than the other L. reuteri strains, while ATCC 
PTA 6475 generally had higher counts. In untreated flour, the bacterial counts 
in the slurries with the six barley varieties were similar for all strains, only 
varying by 0.5 log10 CFU g-1. In heat-treated flour the differences were greater, 
at least for DSM 17938 with bacterial counts ranging from 7.3-8.8 log10 CFU g-
1, while the other strains had similar differences (0.4-0.7 log10 CFU g-1) as in 
untreated flour. While the differences was not great for most bacterial strains, 
they generally grew better in barley variety 224, while they had slightly lower 
bacterial densities in slurries of varieties 120 and 249. Metabolic profiling by 
1H-NMR was performed to visualise potential differences in metabolism seen 
for the different combinations of strains and barley varieties. Multivariate 
statistical analysis (OPLS-DA) of the metabolic profiles of strains from 
untreated flour revealed that the profiles of the sourdough strains formed clusters 
separated from the two strains of human origin (Figure 6).  
 
Figure 6. Orthogonal partial least squares (OPLS-DA) score plot from proton nuclear magnetic 
resonance (1H-NMR) spectrum profiles of all different fermented untreated barley flours. Class 
ID (strain of Lactobacillus reuteri) marked as follows: ATCC PTA 6475 = green; DSM 17938 = 
blue; LTH 5531 = red; SU12-3 = yellow; SU18-3 = cyan.  
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The metabolites mainly responsible for the separation into clusters in untreated 
flour were succinate, lactate, acetate and ethanol. Barley fermented by strain 
DSM 17938 had lower concentrations of succinate than barley fermented by the 
other reuteri strains, while barley fermented by ATCC PTA 6475 had lower 
concentrations of acetate, lactate and ethanol than found with most other strains. 
Lower concentrations of succinate were also seen in heat-treated flours 
fermented by DSM 17938, while only minor differences in other major 
metabolites were seen. The lower succinate concentration could indicate that 
DSM 17938 uses other electron acceptors than fumarate and malate, or that the 
metabolic reaction continues to form lactate from malate, using malolactic 
enzymes (Stolz et al., 1995). 
Although the bacterial counts of the sourdough strains were not higher in 
barley flour than those of the strains of human origin, the differences observed 
in metabolic profiles might indicate a certain degree of adaptation to this 
ecological niche, as suggested in previous studies (Zheng et al., 2015). Tests 
were made for correlations between bacterial densities and nutritional content of 
the barley varieties, based on information on the nutritional content of the 
different barley flours previously obtained by colleagues at the Department of 
Molecular Sciences, as well as data on the sugar and amino acid content provided 
by 1H-NMR. No such correlations were found, but the amount of information 
about each barley variety was very limited and differences in content that might 
explain differences in growth and metabolism could have been missed. Only one 
possible correlation was found, and that was with tryptophan content. In heat-
treated barley flour, the varieties (var.) with the highest bacterial densities (var. 
181 and 224) had the highest tryptophan concentrations, while the varieties with 
the lowest bacterial densities (var. 120 and 249) had lowest tryptophan 
concentrations. The levels of tryptophan were also decreased in barley varieties 
181 (Figure 7) and 224 fermented by L. reuteri and L. plantarum, but not in 
variety 120. These correlations were seen for all but one bacterial strain (ATCC 
PTA 6475). 
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Figure 7. (A) Tryptophan levels (mM) in the different heat-treated barley flours and (B) changes in 
tryptophan levels after fermentation by Lactobacillus reuteri and L. plantarum (36E) in barley 
variety 181. Mean values for three biological replicates. Bars with different letters are significantly 
different (p<0.05). 
3.2 Production of AhR ligands and effect of fermented 
barley slurries in vitro (unpublished) 
Lactobacillus reuteri has been shown to utilise tryptophan under certain 
conditions, leading to the production of bioactive derivatives, some of which are 
called aryl-hydrocarbon receptor (AhR) ligands (Zelante et al., 2013). Those 
authors postulated that utilisation of tryptophan and production of its derivatives 
mainly occur under conditions with high tryptophan levels and low carbohydrate 
levels (carbohydrate starvation). Since the levels of tryptophan were found to 
decrease in some of the fermented barley varieties in Paper I and since the 
availability of fermentable sugars was low in the heat-treated barley flours, more 
targeted chemical analyses were performed. QTOF-LCMS was utilised, since it 
can detect lower concentrations of compounds than 1H-proton NMR. 
Identification of specific compounds can also be made more accurate by adding 
standards of known concentrations for each targeted compound. The results 
revealed that the levels of two AhR ligands (tryptamine and indole-3-aldehyde) 
had increased in heat-treated flour (barley variety 224) fermented by L. reuteri 
DSM 17938 and 6475 compared with unfermented flours (Figure 8).  
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Figure 8. Results (mean ±SEM) of chemical analysis by quadrupole time of flight-liquid 
chromatography mass spectrometry (QTOF-LCMS). Area of identified peaks for tryptamine, 
serotonin, indole-3-aldehyde and tryptophan in whole grain flour from barley variety 224 fermented 
by Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475, compared with fermentation by 
L. plantarum 36E and unfermented barley flour. Bars with different letters are significantly 
different (p<0.05). 
Serotonin, another tryptophan derivative, was also increased in the same 
samples and in flours fermented by L. plantarum 36E. Increases in tryptamine 
were not seen for L. plantarum. For DSM 17938, the increases seen in serotonin 
and tryptamine were correlated with a decrease in tryptophan, but only for 
certain barley flours. Such correlations were not seen at all for ATCC PTA 6475, 
where no or only small decreases in tryptophan were seen, although increases in 
tryptophan derivatives were detected. Similar results, showing increases in 
tryptamine and serotonin, were seen in three consecutive experiments, indicating 
an increase in these compounds in heat-treated barley flour during fermentation 
with L. reuteri. In an attempt to demonstrate actual production, and not merely 
solubilisation, of those compounds in the supernatants, a labelled tryptophan (L-
tryptophan-15N2) was added to the flour-water mixtures during the fermentation 
with L. reuteri. However, none of the labelled derivatives of tryptophan was 
detected after fermentation, even though the levels of labelled tryptophan 
decreased during fermentation of barley varieties 224 and 120 with strains DSM 
17938 and ATCC PTA 6475. While the levels of both tryptamine and serotonin 
increased in barley variety 224, analysis of all six varieties revealed that 
tryptamine levels were increased in all varieties (Figure 9). Serotonin was also 
increased during the fermentation of most barley varieties by both DSM 17938 
and 6475, compared with the unfermented flour-water mixtures. The changes in 
tryptamine levels were highest for barley variety 224. The same was true for 
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serotonin levels fermented by DSM 17938, but not for ATCC PTA 6475, where 
the levels were slightly higher in barley variety 155. Interestingly, the amount of 
soluble tryptophan did not change much during the fermentation with ATCC 
PTA 6475, the levels being close to those in the unfermented flour-water mixture 
for all barley varieties. For DSM 17938, the levels of tryptophan were 
significantly decreased for two of the barley varieties (var. 155 and 224). 
 
Figure 9. Results of chemical analysis by quadrupole time of flight-liquid chromatography mass 
spectrometry (QTOF-LCMS). Fermentation of six different varieties of barley (120, 155, 181, 224, 
228 and 249) by Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475. Bars show the 
ratio between fermented and unfermented samples. 
The importance of AhR ligands in immune responses, as mentioned in 
previous sections, led to the hypothesis that L. reuteri can utilise tryptophan to 
produce AhR ligands during culture in barley flour slurry, which in turn could 
have a protective effect on intestinal epithelial permeability. Evaluations in vitro 
of some of the fermented barley slurries were performed using the intestinal 
epithelial permeability model with IPEC-J2 cells. The results showed that 
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supernatants from one of the combinations of bacteria and heat-treated barley 
flour (120-6475) could have a protective effect on intestinal epithelial cell layer 
integrity (Figure 10). No dose-dependent effects were seen in a follow-up 
experiment, when the amount of added supernatant was increased from 20 µL to 
40, 80 and 150 µL. The protective effect was only seen for leakage of the 
fluorescent macromolecule (FITC-dextran, 4 kDa) and not for transepithelial 
resistance (TEER). No significant delay in decrease in TEER was seen for any 
of the pre-treatments. However, the effect of barley:L. reuteri combinations did 
not correlate to content of AhR ligands, since the best combination (120-6475) 
had one of the lowest levels of tryptamine. The protective effect of the 
supernatant was not as significant as that of the live bacteria (DSM 17938 and 
ATCC PTA 6475), indicating either that the concentrations of the bioactive 
compounds in the supernatants were too low, or that the mechanism behind the 
protective effect in this model is not linked to those bioactive compounds. 
 
 
Figure 10. Results (mean ± SEM) of tests on intestinal epithelial integrity model (IPEC-J2), 
showing leakage of fluorescent molecules (FITC-dextran) across the monolayer. Bars with different 
letters are significantly different (p<0.05). 
3.3 Improvement of DSM 17938 by experimental 
evolution (Papers II and III) 
In Paper II, the focus was on improving certain functional properties of L. reuteri 
DSM 17938 using the experimental evolution approach. Properties to improve 
were chosen based on previously observed limitations of this strain compared 
with others. One crucial property for a commercially produced probiotic strain 
is the survival ability during lyophilisation (freeze-drying), since most products 
are administered in this form. A high percentage of viable bacteria after 
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lyophilisation would mean higher counts in each dose and possibly a greater 
chance of exerting an effect in the gastrointestinal tract. Based on observations 
made in our laboratory by Garcia et al. (unpublished), there is a correlation 
between tolerance to repeated cycles of freezing-thawing and survival ability 
during lyophilisation for DSM 17938. Similar correlations have been observed 
for Lactobacillus plantarum, where a strain with higher freeze-thaw tolerance 
also had higher survival ability during lyophilisation (Schoug, 2009). Studies on 
Bifidobacterium longum pre-treatment with salt show that it can enhance the 
tolerance to freeze-thaw and lethal heat stress (Crittenden, 2004). This indicates 
that the induction of stress proteins during the fermentation of a probiotic strain 
could improve survival ability during other types of stress, during e.g. 
manufacture, storage and gastrointestinal transit. To test this hypothesis, new 
variants with higher freeze-thaw tolerance were isolated during assays and 
compared with the wild type. Two isolates (FT1 and FT2) were used for further 
analyses, of which FT1 formed normal-sized colonies on MRS plates while FT2 
formed slightly smaller colonies. Comparing the freeze-thaw tolerance of these 
two variants to wild-type DSM 17938 revealed that both had an improvement in 
tolerance, with FT2 being the slightly better variant. The new variants of DSM 
17938 had a lower decrease in viable counts by the end of the assay, 
approximately 1.7 log10 CFU mL-1 compared with 2.6 log10 CFU mL-1 for the 
wild-type DSM 17938 (Paper II).  
Two other properties believed to be important for a probiotic bacterium to 
exert a positive effect on the host are bile tolerance and mucus binding capacity. 
In order for probiotic bacteria to metabolise and be active in the intestine of the 
host, they need to survive the passage from the oral cavity down to the small and 
large intestine. Although DSM 17938 has been shown to be one of the most 
potent probiotic bacteria in clinical studies, the strain has a relatively low bile 
tolerance in vitro (Whitehead et al., 2008). The poor tolerance to porcine bile 
seen in Paper II has not been reported previously. Previous studies investigating 
the tolerance to bovine bile have only revealed poor tolerance of DSM 17938 
during the exponential phase, while it was found to tolerate and even grow 
during exposure to bile concentrations up to 5% after reaching the stationary 
phase (Rosander et al., 2008; Whitehead et al., 2008). However, bovine bile has 
been shown to be less inhibitory than porcine bile on other species of 
Lactobacillus (Dunne et al., 2001; Grill et al., 2000). Similar results have been 
reported for Helicobacter hepaticus, i.e. less inhibition during incubation with 
bovine bile salts compared with porcine and human bile salts (Okoli et al., 2012; 
Okoli et al., 2010). The lower inhibition of bovine bile compared with porcine 
bile on other bacteria, and especially other lactobacilli, suggests that porcine bile 
might be a better choice when evaluating human bile tolerance, since some 
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studies claim that porcine and human bile are more similar in inhibitory effect 
and in composition (Begley et al., 2005). The low tolerance to 0.5% (w/v) 
porcine bile of DSM 17938 in Paper II was significantly improved through 
experimental evolution (Figure 11).  
 
Figure 11. Decrease in viable counts, expressed as log10 CFU mL-1 (mean ± SEM), of 
Lactobacillus reuteri strain DSM 17938 wild type and variants BT5, BT6 and FT2 during 
exposure to 0.5% (w/v) porcine bile for 240 minutes. Marker points with different letters are 
significantly different (p<0.05). 
Several new variants of DSM 17938 were isolated during the bile tolerance 
assay, and two were chosen for additional analyses. These were BT5, which 
formed normal-sized colonies, and BT6, which formed small-sized colonies. 
These two variants and variant FT2 were tested again and compared with wild-
type DSM 17938. The results revealed that two of the variants (BT6 and FT2) 
had a decrease in viable counts of approximately 0.5 log10 CFU mL-1, compared 
with 3.5 log10 CFU mL-1 for the wild type. 
The genome analysis performed on variants FT2 and BT6 only revealed 
changes for FT2 compared with wild-type DSM 17938. An insertion of one 
nucleotide that caused a frameshift in a gene encoding a glycosyltranferase 
(wcaA) was detected. This gene is truncated in wild-type DSM 17938 and the 
insertion of the nucleotide seems to have made the gene intact again. Little is 
known about the function of WcaA in lactobacilli, but it is suggested to play a 
role in fatty acid or lipid synthesis (Yang et al., 2017). The proteomic analyses 
of the two variants revealed more changes compared with wild-type DSM 
17938. The results for the freeze-thaw tolerant variant FT2 and the bile tolerant 
BT6 were similar, and changes were mainly seen as protein downregulations in 
an operon of genes (acc, fabD, acp, fabH, fabG, fabF, fabZ and fabI) all related 
to type II fatty acid synthesis (Zhang & Rock, 2008). Changes in the gene 
sequence and expression of proteins related to fatty acid synthesis could indicate 
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possible changes in the lipid composition of the cell membrane. Changes in fatty 
acid composition, causing changes in cell membrane fluidity, have been 
observed in Gram-positive bacteria during different kinds of stress (Pepi et al., 
2008; Williams et al., 2007; Nielsen et al., 2005). In Paper II, induction of a 
protein belonging to the family of MFS transporters was also seen for variants 
FT2 and BT6. Proteins belonging to the family of MFS transporters have been 
shown to contribute to tolerance to bile salt stress in E. coli (Paul et al., 2014).  
Interestingly, a trend was seen for new variants with an increased tolerance 
to both freeze-thaw and bile, as it appeared that variants derived from smaller-
sized colonies had a higher tolerance to both types of stresses. This observation 
was further investigated in Paper III, where the growth kinetics of the new 
variants were compared with those of wild-type DSM 17938. By following the 
changes in optical density during cultivation under normal conditions, it was 
found that the two new variants derived from smaller-sized colonies indeed had 
changes in their growth kinetics. They had a longer lag phase compared with 
wild-type DSM 17938 (Figure 12), and also had a lower final optical density 
(data not shown). The variant derived from a large colony (BT5), on the other 
hand, had a growth curve which was similar to that of wild-type DSM 17938.  
 
Figure 12. Growth curves (change in optical density measured at 600 nm (OD600)) of Lactobacillus 
reuteri strain DSM 17938 wild type and variants FT2, BT5 and BT6 during a 12-hour cultivation 
in de Man, Rogosa and Sharpe (MRS) broth at 37 °C. Mean ± SEM of six biological replicates from 
one experiment. Marker points with different letters are significantly different (p<0.05). 
In Paper III, the observation made by Garcia et al. (unpublished) that higher 
freeze-thaw tolerance correlates to higher survival ability during lyophilisation 
was evaluated for the new variant FT2 compared with wild-type DSM 17938 
(Table 3). One candidate from each of the other groups of variants was also 
tested, to investigate any changes in those. Most of the new variants did not 
significantly differ in survival ability compared with wild-type DSM 17938 
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(54.64%). However, the combination variant MFT3 had the highest survival 
ability (69.19%), significantly higher than all except variant BT6. Surprisingly, 
FT2 had the lowest survival ability (47.78%), which might indicate that the 
original hypothesis of a correlation between freeze-thaw tolerance and survival 
during lyophilisation is false. An earlier study suggested that this hypothesis 
might be true (Schoug, 2009), but other studies have reported a negative 
correlation, indicating that strains with higher freeze-thaw tolerance could have 
lower storage stability after lyophilisation (Sawicki, 2017). 
Table 3. Viable counts (log10 CFU mL-1) of Lactobacillus reuteri strain DSM 17938 wild type and 
variants FT2, MFT3, MB4 and BT6 after lyophilisation in a 10% sucrose solution. Mean values ± 
SEM of four replicates (two biological and two technical replicates). Values with different letters 
are significantly different (p<0.05) 
Bacterial variant Initial counts After lyophilisation % survival 
WT 10.13 ± 0.01 9.87 ± 0.02 54.6B 
FT2 10.03 ± 0.02 9.71 ± 0.03 47.8B 
MFT3 9.97 ± 0.03 9.81 ± 0.02 69.2A 
MB4 10.12 ± 0.02 9.82 ± 0.02 51.1B 
BT6 10.04 ± 0.01 9.80 ± 0.03 57.9AB 
 
However, during the five-week stability test of each variant, FT2, BT6 and 
wild-type DSM 17938 had almost identical values for the viability counts. 
Variant MFT3 showed better stability for three weeks, but at the last time point 
(five weeks) its viable counts dropped sharply. In order to study whether the 
differences between the new variants and wild-type DSM 17938 were in 
activation time, rather than viable counts, the growth kinetics of the lyophilised 
cultures during normal cultivation conditions were analysed. The results showed 
similar results as seen in Figure 12, with longer lag phase for FT2 and BT6, but 
this time the final optical density was the same for all variants. According to the 
results in Paper III, variants with higher tolerance to repeated cycles of freeze-
thaw are not necessarily more tolerant to the stressful conditions during the 
lyophilisation process.  
In addition to maintaining viable counts at as high a level as possible when 
passing through the gastrointestinal tract, it is also important for probiotic 
bacteria to be able to stay in the small and large intestine long enough to exert 
an effect on the host. In order to remain in the intestine and also to come into as 
close as possible contact with the epithelium and/or the immune cells, the 
bacteria need to adhere, preferably to the mucus layer produced by the mucosal 
membranes of the intestine. Compared with other strains of reuteri, the mother 
strain of DSM 17938, named ATC 55730 or SD 2112 (Rosander et al., 2008), 
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has been shown to have low mucus binding capacity (Saulnier et al., 2011; 
Jonsson et al., 2001), similar to that of DSM 17938 (Rosander et al., 2008).  
 
 
Figure 13. Mucus binding capacity of Lactobacillus reuteri strain DSM 17938 and new variants 
MB4 and MFT3 compared with strain ATCC PTA 6475, previously shown to be a good mucus 
binder. The capacity is shown as log10 CFU cm-2 (mean ±SEM). Bars with different letters are 
significantly different (p<0.05). 
The results presented in Paper II showed that DSM 17938 indeed has a low 
mucus binding capacity in vitro, but that this could be improved 10-fold by the 
use of experimental evolution (Figure 13). Several variants of DSM 17938 were 
isolated during the mucus binding assay and saved. Two of those variants were 
used for further analyses. These were MB4, a ‘pure’ mucus binding variant, and 
MFT3, a mucus binding variant of the existing freeze-thaw variant FT2. The two 
new variants had a binding capacity of approximately 6.5 log10 CFU cm-2, 
compared with 5 log10 CFU cm-2 for the wild type. An explanation for the 
increased mucus binding capacity of the new variants of DSM 17938 could not 
be found in the genomic data. However, proteomic analysis of variant MB4 
revealed a few proteins which could possibly explain the new and improved 
phenotype. A protein similar to MsbA, an aminotransferase involved in lipid A 
and lipopolysaccharide transport in Gram-negative bacteria (Eckford & Sharom, 
2010), was induced for MB4. MsbA has also been suggested to play a role in 
glycerophospholipid transport from the inner to the outer membrane of E. coli 
(Zhou et al., 1998). Lipid A and LPS is not present in the cell wall of Gram-
positive bacteria, but the presence of proteins similar to MsbA in L. reuteri 
indicate that it may also be involved in the transport of other lipids in lactobacilli. 
In addition to this protein, a LysM peptidoglycan-binding domain-containing 
protein was induced in MB4. This protein was similar in sequence to a 
previously described peptidoglycan endopeptidase present in L. reuteri. These 
enzymes are cell wall hydrolases, which have been show to correlate to increased 
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adhesion to hydrophobic surfaces for Lactococcus lactis and Staphylococcus 
aureus (Porayath et al., 2018; Vollmer et al., 2008; Mercier et al., 2002).  
Another plausible explanation for the increase in adhesion could be a change 
in other functional properties of DSM 17938. For variants MB4 and MFT3, an 
increase in hydrophobicity was seen compared with wild-type DSM 17938 
(Paper III). A correlation between cell surface hydrophobicity and mucus 
adhesion has been demonstrated in a number of studies (Kos et al., 2003; 
Ehrmann et al., 2002; Del Re et al., 2000; Wadstroum et al., 1987b). When 
grown in MRS broth, another difference between MB4 and MFT3 compared 
with wild-type DSM 17938 was observed, in that overnight cultures of MB4 and 
MFT3, cultivated under normal conditions in either small glass tubes or large 
glass bottles, formed aggregates (Figure 14). Previous studies have observed that 
strains with higher mucus binding capacity also have significantly higher 
aggregation levels (Lukić et al., 2012; MacKenzie et al., 2010). 
 
Figure 14. Aggregation seen in new variants of Lactobacillus reuteri strain DSM 17938 when 
cultivated in de Man, Rogosa and Sharpe (MRS) broth. (A) DSM 17938, (B and C) MB4 and 
(D) MFT3. 
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3.4 Evaluation of new DSM 17938 variants in vitro 
(Paper III) 
In order to investigate whether other characteristics with possible connections to 
host-microbe interactions had been affected during the improvement process, 
DSM 17938 variants were evaluated using different in vitro models. Intestinal 
epithelial cell models were chosen to investigate whether the new variants with 
increased mucus binding capacity had increased binding capacity to host cells. 
The adhesion of Lactobacillus and other probiotic bacteria to intestinal epithelial 
cells is suggested to play a role in pathogen removal, by e.g. reducing the number 
of binding sites (Liu et al., 2015; Roselli et al., 2007). Wild-type DSM 17938 
and the two variants with improved mucus binding capacity (MB4 and MFT3) 
were evaluated in both IPEC-J2 and Caco-2 cell models in Paper III. MB4 had 
similar adhesion to both cell lines as wild-type DSM 17938, while MFT3 had 
significantly lower binding capacity. According to these results, there is no 
correlation between mucus adhesion and epithelial cell adhesion, indicating 
different mechanisms for binding. One study has found a few proteins in L. 
reuteri that are involved in adhesion to mucus and to epithelial cells (Jensen et 
al., 2014). However, since none of these proteins was found to be upregulated 
for MB4, and since only the mucus binding capacity was improved for this 
variant and not the adhesion to Caco-2 or IPEC-J2, the mechanism behind the 
adhesion is more likely due to other interactions. There are several other proteins 
with a possible role in adhesion of Lactobacillus to both mucus and epithelial 
cell lines, but none of these was found to be upregulated in the variants tested. 
There could instead be non-specific physical interactions behind the increased 
adhesion in MB4 and MFT3. Studies have shown correlations between adhesion 
to the small intestine of pigs (Wadstroum et al., 1987a), porcine ileal epithelial 
cells (Kos et al., 2003), human epithelial cell lines such as HT-29 (VIZOSO 
PINTO et al., 2007) and cell surface hydrophobicity of the bacteria. A study on 
Lactobacillus rhamnosus GG has shown though, that reduced hydrophobicity of 
the strain has only a minor reducing effect on the adhesion to Caco-2 (Deepika 
et al., 2009). This indicates that there may be a correlation between 
hydrophobicity and mucus binding capacity, but that it does not necessarily 
always correlate with epithelial cell adherence. 
In intestinal permeability assays with IPEC-J2 cells, previous results have 
indicated that DSM 17938 has a protective effect against the increased 
permeability caused by ETEC (Karimi et al., 2018). The experiments in Paper 
III confirmed those results, which were then compared with the results for the 
new variants. The results for the IPEC-J2 model revealed differences in the 
protective effect of some of the variants compared with the wild type (Figure 
15). The mucus binding variant MB4 showed similar results to wild-type DSM 
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17938, while the bile tolerant (BT6) and freeze-thaw tolerant (FT2) variants 
showed no protective effects against ETEC. Pre-treatment with MFT3 did not 
give significant differences from the cells which only received the ETEC 
challenge, but there was a tendency for a protective effect. The lower protective 
effects of MFT3 compared with MB4 and wild-type DSM 17938 could possibly 
be explained by lower adhesion to IPEC-J2, since other studies have reported 
correlations between adhesion of ETEC and its effects on pro-inflammatory 
cytokine production (Kšonžeková et al., 2016). In that study, lower adhesion of 
ETEC led to lower production of pro-inflammatory IL-1β and IL-6, after 
treatment with exopolysaccharides produced by DSM 17938.  
 
 
 
Figure 15. Results (mean ± SEM) showing leakage of fluorescent macromolecule FITC-dextran 
(4 kDa) during a permeability experiment using IPEC-J2 cells. Before challenge with ETEC, cells 
were either pre-treated with Lactobacillus reuteri strain DSM 17938 and new variants MB4, MFT3, 
BT6 and FT2, or not pre-treated (ETEC). Bars with different letters are significantly different 
(p<0.05). 
The hypothesis that a variant of DSM 17938 with increased mucus binding 
capacity would also have higher adhesion to intestinal cells and a better 
protective effect against ETEC could not be proven in Paper III. While the mucus 
binding capacity was improved for MB4, the adhesion to cells was not. The 
protective effect against ETEC was not improved either for this variant, with 
results similar to those for DSM 17938. However, since IPEC-J2 is a cell line 
that does not produce any mucus (Schierack et al., 2006), MB4 could have a 
better effect on mucus producing cell lines such as LS174T (MUC2) (Hatayama 
et al., 2007). Administration of L. reuteri has been shown to lower the expression 
of pro-inflammatory cytokines both in vitro and in vivo (Karimi et al., 2018; 
Bene et al., 2017; Gao et al., 2016; Zelante et al., 2013). Since better adhesion 
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to mucus could allow a longer time to interact with immune cells, the mucus 
binding variants could be hypothesised to have a better inhibitory effect on the 
expression of pro-inflammatory cytokines. 
The new variants were also evaluated for their effect in a cell model to study 
the possible effect on visceral pain, the TRPV1 model. The TRPV1 receptor has 
been shown to be upregulated in people with irritable bowel syndrome and is 
believed to be involved in visceral hypersensitivity (Akbar et al., 2008). Since 
DSM 17938 has been shown to have a good effect against infantile colic, where 
one of the possible causes is believed to be painful intestinal contractions 
(Szajewska et al., 2013; Savino et al., 2010), the inhibition of the TRPV1 
receptor might be one of the possible mechanisms behind this effect. Pre-treating 
Jurkat cells with DSM 17938 and the different variants (FT2, BT6, MB4 and 
MFT3) resulted in a reduction in activation of the TRPV1 receptors by capsaicin 
(Figure 16). 
 
Figure 16. Results (mean ±SEM) from the visceral pain receptor model, using Jurkat cells 
expressing the TRPV1 receptor, showing Fluo-3/FuraRed ratios as values for calcium ion (Ca2+) 
influx. Before challenge with capsaicin, cells were either pre-treated with Lactobacillus reuteri 
strain DSM 17938 and new variants FT2, BT6, MB4 and MFT3 with two ratios of bacteria/Jurkat 
cells (20:1 = light colour, 50:1 = dark colour) or not pre-treated (Control). Bars with different 
letters are significantly different (p<0.05).  
Two ratios of bacteria to Jurkat cells were studied and both had an effect on 
the TRPV1 receptors, with a slightly larger decrease in Ca2+ influx in the ratio 
50:1 compared with 20:1 for most variants. A previous study has suggested that 
DSM 17938 mediates its effect on TRPV1 receptors by secretion or shedding of 
products, since supernatants from cultures of DSM 17938 have similar effects 
as live bacteria, while dead bacteria have no effect (Perez‐Burgos et al., 2015). 
Those authors suggest that microvesicles produced by the bacteria might confer 
this effect. This would also explain how luminal bacteria could influence the 
enteric nervous system and have an effect in vivo, since microvesicles are small 
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enough to diffuse through the mucus layer and intestinal monolayer. To explain 
why no differences were seen between the new variants and wild-type DSM 
17938, it might be necessary to analyse the production and content of 
microvesicles for each new variant compared with wild-type DSM 17398, which 
has been done for DSM 17938 in another study (Grande et al., 2017). 
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As a probiotic, L. reuteri is one of the most clinically studied bacteria, with 
positive effects against a number of different diseases and disorders and the best 
documented effects seen against infantile colic. Infantile colic and a number of 
other gastrointestinal diseases are suggested to be connected to a leaky gut 
(increased intestinal permeability). Both in vitro and in vivo studies using animal 
and cell models have shown that this increase in permeability can be reduced or 
even normalised by the use of probiotic bacteria and compounds produced by 
these bacteria.  
Paper I investigated whether cultivation of L. reuteri in a cereal-based 
substrate could stimulate the bacteria into producing compounds with possible 
biological activity, i.e. production of bioactive compounds. Fermentation of 
barley varieties with different characteristics, with strains of L. reuteri of 
different origin were made. The impact of nutrient content and strain properties 
as well as ecological background on the bacterial densities and metabolic 
processes were evaluated. The results revealed some degree of strain adaptation 
to a specific niche in L. reuteri, but the differences between the strains were 
relatively small, both in the effect on bacterial densities and on metabolic 
profiles. The impact of the substrate was great for some strains, but not for 
others. Correlations between the presence of higher levels of tryptophan and 
increased growth were seen for DSM 17938 and to some degree for the other 
strains. The supernatants from these combinations were shown to contain 
different levels of tryptophan catabolites, which have previously been shown to 
be bioactive compounds with effects on innate immune responses in animal 
models. Further experiments are needed to confirm production of those 
catabolites in barley fermented by L. reuteri, as only increased concentrations of 
these catabolites could be observed. Tests on the effect of possible bioactive 
compounds produced during the fermentation of barley revealed only minor 
protective effects on the permeability induced by ETEC after pre-treatment with 
some supernatants from barley flour fermented by L. reuteri. No correlations to 
4 Conclusions and future perspectives 
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a specific content of bioactive compounds were found. Optimisation of 
production of such bioactive compounds may be needed, since the levels might 
have been too low to exert an effect in the models. 
The majority of clinical studies investigating the probiotic effect of L. reuteri 
have been performed on strain DSM 17938. While it has good clinical effects, 
there are certain functional properties of the strain which, if improved, might 
improve the host-microbe interactions. Bile tolerance and mucus binding 
capacity are two properties for which some other strains of L. reuteri outperform 
DSM 17938. In Paper II, experimental evolution was used as a tool to isolate 
new variants of DSM 17938 with improved tolerance to porcine bile and with 
higher adhesion to porcine mucus. Another more technical property (freeze-thaw 
tolerance) was also improved for variants of DSM 17938. Combined tolerance 
to freeze-thaw stress and increased mucus binding was found in one variant. The 
new variants were shown to have no or only few changes in the genome 
sequence, indicating a low mutation rate. Analyses of the proteome, on the other 
hand, revealed changes for all variants compared with the wild type, with the 
bile tolerant and freeze-thaw tolerant variants being very similar in protein 
expression, while the mucus binding variant had changes in other proteins. The 
changes in the bile and freeze-thaw tolerant variants were mainly suppression of 
an operon of genes involved in type II fatty acid synthesis and the induction of 
a MFS transporter protein possibly involved in increased bile tolerance. For the 
mucus binding variant, the analysis revealed induction of a protein with a 
possible involvement in glycerophospholipid transport in Gram-negative 
bacteria and proteins involved in cell wall hydrolysis that is involved in adhesion 
to hydrophobic surfaces in other lactic acid bacteria. No changes in proteins 
known to be involved in mucus binding were seen, and use of an alternative 
technique, such as bacterial surface shaving followed by analysis of the released 
proteins, might be needed to identify more changes in the membrane and cell 
wall proteome. Repeating the initial experiments with knock-out mutants of 
DSM 17938 with inactivations of the genes believed to be involved in stress 
tolerance and mucus binding may also be needed, to confirm the assumptions 
made in Paper II.  
In Paper III, the new variants with improved functional properties were 
studied in different in vitro models, to determine possible changes in other 
characteristics and to study the effect of the variants on intestinal permeability 
and pain receptor TRPV1 compared with wild-type DSM 17938. A possible 
connection between freeze-thaw tolerance and ability to survive lyophilisation 
was tested, but no clear correlations were seen. A possible connection between 
colony size and tolerance to bile and freeze-thaw was detected during the initial 
experiments in Paper II. Variants derived from small colonies generally had a 
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higher tolerance to both bile and freeze-thaw stress than variants derived from 
normal-sized colonies. The hypothesis that better stress tolerance could come at 
the cost of disturbed growth was confirmed in Paper III, which showed a longer 
lag phase and lower final optical density of variants derived from small colonies. 
Previously reported correlations between higher hydrophobicity and increased 
mucus binding were confirmed for the mucus binding variants, but no increased 
binding to intestinal epithelial cells was seen for the variants compared with 
wild-type DSM 17938. The protective effect of wild-type DSM 17938 against 
increased intestinal permeability was also seen in one of the mucus binding 
variants, but was significantly lower in the bile and freeze-thaw tolerant variants. 
The differences in protective effects for some variants could partly be explained 
by differences in adhesion to the intestinal epithelial cells. In contrast, there were 
no differences between the new variants compared with wild-type DSM 17938 
in the inhibitory effect on pain receptor TRPV1. 
In future studies, the importance of the new properties in actual colonisation 
of the gastrointestinal tract of both animals and humans should be evaluated for 
the variants produced in this thesis, by studying biopsies from different parts of 
the intestine for the presence of L. reuteri. Previous studies have successfully 
studied colonisation by ATCC 55730 using 16S molecular beacon probes shown 
to be species-specific (Valeur et al., 2004). A less invasive way could be to 
determine the effect of colonisation of the new variants, and not actual 
colonisation. This could be done by repeating earlier animal and human studies, 
where increased mucus binding capacity could be hypothesised to play an 
important role, e.g. in studies on inflammatory intestinal diseases where immune 
responses (e.g. expression of pro-inflammatory cytokines) play a crucial role 
(Neurath, 2014). 
  
62 
 
 
63 
 
 
Adawi, D., Kasravi, F.B., Molin, G. & Jeppsson, B. (1997). Effect of Lactobacillus 
supplementation with and without arginine on liver damage and bacterial translocation in an 
acute liver injury model in the rat. Hepatology, 25(3), pp. 642-647. 
Akbar, A., Yiangou, Y., Facer, P., Walters, J.R., Anand, P. & Ghosh, S. (2008). Increased 
capsaicin receptor TRPV1 expressing sensory fibres in irritable bowel syndrome and their 
correlation with abdominal pain. Gut. 
Akiba, Y., Guth, P.H., Engel, E., Nastaskin, I. & Kaunitz, J.D. (2000). Dynamic regulation of 
mucus gel thickness in rat duodenum. American Journal of Physiology-Gastrointestinal and 
Liver Physiology, 279(2), pp. G437-G447. 
Alakomi, H.-L., Skyttä, E., Saarela, M., Mattila-Sandholm, T., Latva-Kala, K. & Helander, I. 
(2000). Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. 
Applied and Environmental Microbiology, 66(5), pp. 2001-2005. 
Antikainen, J., Korhonen, T.K., Kuparinen, V., Toba, T., Roos, S., Ljungh, Å. & Wadstrom, T. 
(2009). Surface proteins of Lactobacillus involved in host interactions. Lactobacillus 
molecular biology: from genomics to probiotics, Ljungh A, Wadström T. Eds, pp. 95-114. 
Athalye-Jape, G., Rao, S. & Patole, S. (2018). Effects of probiotics on experimental necrotizing 
enterocolitis: a systematic review and meta-analysis. Pediatric research, 83(1-1), p. 16. 
Atuma, C., Strugala, V., Allen, A. & Holm, L. (2001). The adherent gastrointestinal mucus gel 
layer: thickness and physical state in vivo. American Journal of Physiology-Gastrointestinal 
and Liver Physiology, 280(5), pp. G922-G929. 
Axelsson, L., Chung, T., Dobrogosz, W. & Lindgren, S. (1989). Production of a broad spectrum 
antimicrobial substance by Lactobacillus reuteri. Microbial ecology in health and disease, 
2(2), pp. 131-136. 
Balzan, S., de Almeida Quadros, C., De Cleva, R., Zilberstein, B. & Cecconello, I. (2007). 
Bacterial translocation: overview of mechanisms and clinical impact. Journal of 
gastroenterology and hepatology, 22(4), pp. 464-471. 
Beasley, D.E., Koltz, A.M., Lambert, J.E., Fierer, N. & Dunn, R.R. (2015). The evolution of 
stomach acidity and its relevance to the human microbiome. PloS one, 10(7), p. e0134116. 
Begley, M., Gahan, C.G. & Hill, C. (2005). The interaction between bacteria and bile. FEMS 
Microbiology Reviews, 29(4), pp. 625-651. 
References 
64 
 
Begley, M., Hill, C. & Gahan, C.G. (2006). Bile salt hydrolase activity in probiotics. Applied and 
Environmental Microbiology, 72(3), pp. 1729-1738. 
Bene, K.P., Kavanaugh, D.W., Leclaire, C., Gunning, A.P., MacKenzie, D.A., Wittmann, A., 
Young, I.D., Kawasaki, N., Rajnavolgyi, E. & Juge, N. (2017). Lactobacillus reuteri surface 
mucus adhesins upregulate inflammatory responses through interactions with innate C-type 
lectin receptors. Frontiers in microbiology, 8, p. 321. 
Berg, R.D. (1995). Bacterial translocation from the gastrointestinal tract. Trends in microbiology, 
3(4), pp. 149-154. 
Berschneider, H. (1989). Development of normal cultured small intestinal epithelial cell lines 
which transport Na and Cl. Gastroenterology, 96, p. A41. 
Bertin, S., Aoki-Nonaka, Y., De Jong, P.R., Nohara, L.L., Xu, H., Stanwood, S.R., Srikanth, S., 
Lee, J., To, K. & Abramson, L. (2014). The ion channel TRPV1 regulates the activation and 
proinflammatory properties of CD4+ T cells. Nature immunology, 15(11), p. 1055. 
Biesalski, H.-K., Dragsted, L.O., Elmadfa, I., Grossklaus, R., Müller, M., Schrenk, D., Walter, P. 
& Weber, P. (2009). Bioactive compounds: Definition and assessment of activity. Nutrition, 
25(11–12), pp. 1202-1205. 
Bjarnason, I., Macpherson, A. & Hollander, D. (1995). Intestinal permeability: an overview. 
Gastroenterology, 108(5), pp. 1566-1581. 
Bjarnason, I., Peters, T. & Veall, N. (1983). A PERSISTENT DEFECT IN INTESTINAL 
PERMEABILITY IN COELIAC DISEASE DEMONSTRATED BY A< sup> 51</sup> Cr-
LABELLED EDTA ABSORPTION TEST. The Lancet, 321(8320), pp. 323-325. 
Blaabjerg, S., Artzi, D.M. & Aabenhus, R. (2017). Probiotics for the Prevention of Antibiotic-
Associated Diarrhea in Outpatients—A Systematic Review and Meta-Analysis. Antibiotics, 
6(4), p. 21. 
C., M.T., Kåre, B. & L., W.H. (2005). Gastric Juice: A Barrier Against Infectious Diseases. Basic 
& Clinical Pharmacology & Toxicology, 96(2), pp. 94-102. 
Camilleri, M., Lasch, K. & Zhou, W. (2012). Irritable bowel syndrome: methods, mechanisms, 
and pathophysiology. The confluence of increased permeability, inflammation, and pain in 
irritable bowel syndrome. American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 303(7), pp. G775-G785. 
Carvalho, A.S., Silva, J., Ho, P., Teixeira, P., Malcata, F.X. & Gibbs, P. (2004). Relevant factors 
for the preparation of freeze-dried lactic acid bacteria. International Dairy Journal, 14(10), 
pp. 835-847. 
Cervantes-Barragan, L., Chai, J.N., Tianero, M.D., Di Luccia, B., Ahern, P.P., Merriman, J., 
Cortez, V.S., Caparon, M.G., Donia, M.S. & Gilfillan, S. (2017). Lactobacillus reuteri 
induces gut intraepithelial CD4+ CD8αα+ T cells. Science, 357(6353), pp. 806-810. 
Chen, S., Ferguson, L.R., Shu, Q. & Garg, S. (2011). The application of flow cytometry to the 
characterisation of a probiotic strain Lactobacillus reuteri DPC16 and the evaluation of sugar 
preservatives for its lyophilization. LWT-Food Science and Technology, 44(9), pp. 1873-
1879. 
Chung, T., Axelsson, L., Lindgren, S. & Dobrogosz, W. (1989). In vitro studies on reuterin 
synthesis by Lactobacillus reuteri. Microbial ecology in health and disease, 2(2), pp. 137-
144. 
65 
 
Claesson, M.J., Jeffery, I.B., Conde, S., Power, S.E., O’connor, E.M., Cusack, S., Harris, H.M., 
Coakley, M., Lakshminarayanan, B. & O’sullivan, O. (2012). Gut microbiota composition 
correlates with diet and health in the elderly. Nature, 488(7410), p. 178. 
Clayton, T.A., Lindon, J.C., Cloarec, O., Antti, H., Charuel, C., Hanton, G., Provost, J.-P., Le 
Net, J.-L., Baker, D. & Walley, R.J. (2006). Pharmaco-metabonomic phenotyping and 
personalized drug treatment. Nature, 440(7087), pp. 1073-1077. 
Cleusix, V., Lacroix, C., Vollenweider, S. & Le Blay, G. (2007). Glycerol induces reuterin 
production and decreases Escherichia coli population in an in vitro model of colonic 
fermentation with immobilized human feces. FEMS Microbiol Ecol, 63(1), pp. 56-64. 
Coccorullo, P., Strisciuglio, C., Martinelli, M., Miele, E., Greco, L. & Staiano, A. (2010). 
Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-
blind, randomized, placebo-controlled study. The Journal of pediatrics, 157(4), pp. 598-602. 
Coda, R., Rizzello, C.G. & Gobbetti, M. (2010). Use of sourdough fermentation and pseudo-
cereals and leguminous flours for the making of a functional bread enriched of γ-
aminobutyric acid (GABA). International Journal of Food Microbiology, 137(2), pp. 236-
245. 
Corsetti, A. & Settanni, L. (2007). Lactobacilli in sourdough fermentation. Food Research 
International, 40(5), pp. 539-558. 
Crittenden, R. (2004). An update on probiotic bifidobacteria. FOOD SCIENCE AND 
TECHNOLOGY-NEW YORK-MARCEL DEKKER-, 139, pp. 125-158. 
Cuello-Garcia, C.A., Brożek, J.L., Fiocchi, A., Pawankar, R., Yepes-Nuñez, J.J., Terracciano, L., 
Gandhi, S., Agarwal, A., Zhang, Y. & Schünemann, H.J. (2015). Probiotics for the prevention 
of allergy: a systematic review and meta-analysis of randomized controlled trials. Journal of 
Allergy and Clinical immunology, 136(4), pp. 952-961. 
Dal Bello, F., Clarke, C., Ryan, L., Ulmer, H., Schober, T., Ström, K., Sjögren, J., Van Sinderen, 
D., Schnürer, J. & Arendt, E. (2007). Improvement of the quality and shelf life of wheat bread 
by fermentation with the antifungal strain Lactobacillus plantarum FST 1.7. Journal of 
Cereal Science, 45(3), pp. 309-318. 
De Smet, I., Van Hoorde, L., Vande Woestyne, M., Christiaens, H. & Verstraete, W. (1995). 
Significance of bile salt hydrolytic activities of lactobacilli. Journal of applied bacteriology, 
79(3), pp. 292-301. 
Deepika, G., Green, R.J., Frazier, R.A. & Charalampopoulos, D. (2009). Effect of growth time on 
the surface and adhesion properties of Lactobacillus rhamnosus GG. J Appl Microbiol, 
107(4), pp. 1230-1240. 
Del Re, B., Sgorbati, B., Miglioli, M. & Palenzona, D. (2000). Adhesion, autoaggregation and 
hydrophobicity of 13 strains of Bifidobacterium longum. Lett Appl Microbiol, 31(6), pp. 438-
442. 
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X. & Zhang, T. (2017). The “golden 
age” of probiotics: a systematic review and meta-analysis of randomized and observational 
studies in preterm infants. Neonatology, 112(1), pp. 9-23. 
Dicksved, J., Schreiber, O., Willing, B., Petersson, J., Rang, S., Phillipson, M., Holm, L. & Roos, 
S. (2012). Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment 
despite mucus layer dysfunction. PloS one, 7(9), p. e46399. 
66 
 
Dikkers, A. & Tietge, U.J. (2010). Biliary cholesterol secretion: more than a simple ABC. World 
journal of gastroenterology: WJG, 16(47), p. 5936. 
Dominguez-Bello, M.G., Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. & 
Knight, R. (2010). Delivery mode shapes the acquisition and structure of the initial 
microbiota across multiple body habitats in newborns. Proceedings of the National Academy 
of Sciences, 107(26), pp. 11971-11975. 
Duar, R.M., Lin, X.B., Zheng, J., Martino, M.E., Grenier, T., Pérez-Muñoz, M.E., Leulier, F., 
Gänzle, M. & Walter, J. (2017). Lifestyles in transition: evolution and natural history of the 
genus Lactobacillus. FEMS Microbiology Reviews, 41(Supp_1), pp. S27-S48. 
Dueñas, M., Fernández, D., Hernández, T., Estrella, I. & Muñoz, R. (2005). Bioactive phenolic 
compounds of cowpeas (Vigna sinensis L). Modifications by fermentation with natural 
microflora and with Lactobacillus plantarum ATCC 14917. Journal of the Science of Food 
and Agriculture, 85(2), pp. 297-304. 
Dunlop, S.P., Hebden, J., Campbell, E., Naesdal, J., Olbe, L., Perkins, A.C. & Spiller, R.C. 
(2006). Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable 
bowel syndromes. Am J Gastroenterol, 101(6), pp. 1288-1294. 
Dunne, C., O'Mahony, L., Murphy, L., Thornton, G., Morrissey, D., O'Halloran, S., Feeney, M., 
Flynn, S., Fitzgerald, G. & Daly, C. (2001). In vitro selection criteria for probiotic bacteria of 
human origin: correlation with in vivo findings–. The American journal of clinical nutrition, 
73(2), pp. 386s-392s. 
Dussurget, O., Cabanes, D., Dehoux, P., Lecuit, M., Consortium, E.L.G., Buchrieser, C., Glaser, 
P. & Cossart, P. (2002). Listeria monocytogenes bile salt hydrolase is a PrfA‐regulated 
virulence factor involved in the intestinal and hepatic phases of listeriosis. Molecular 
microbiology, 45(4), pp. 1095-1106. 
Eckford, P.D. & Sharom, F.J. (2010). The reconstituted Escherichia coli MsbA protein displays 
lipid flippase activity. Biochemical Journal, 429(1), pp. 195-203. 
Edwards, U., Rogall, T., Blöcker, H., Emde, M. & Böttger, E.C. (1989). Isolation and direct 
complete nucleotide determination of entire genes. Characterization of a gene coding for 16S 
ribosomal RNA. Nucleic Acids Research, 17(19), pp. 7843-7853. 
Ehrmann, M., Kurzak, P., Bauer, J. & Vogel, R. (2002). Characterization of lactobacilli towards 
their use as probiotic adjuncts in poultry. J Appl Microbiol, 92(5), pp. 966-975. 
Fijan, S. (2014). Microorganisms with claimed probiotic properties: an overview of recent 
literature. International journal of environmental research and public health, 11(5), pp. 4745-
4767. 
Finegold, S.M. (2008). Therapy and epidemiology of autism–clostridial spores as key elements. 
Medical hypotheses, 70(3), pp. 508-511. 
Floch, M.H. & Hong-Curtiss, J. (2002). Probiotics and functional foods in gastrointestinal 
disorders. Current treatment options in gastroenterology, 5(4), pp. 311-321. 
Fogh, J., Wright, W.C. & Loveless, J.D. (1977). Absence of HeLa cell contamination in 169 cell 
lines derived from human tumors. Journal of the National Cancer Institute, 58(2), pp. 209-
214. 
Francavilla, R., Lionetti, E., Castellaneta, S.P., Magistà, A.M., Maurogiovanni, G., Bucci, N., De 
Canio, A., Indrio, F., Cavallo, L. & Ierardi, E. (2008). Inhibition of Helicobacter pylori 
67 
 
infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: 
a pilot study. Helicobacter, 13(2), pp. 127-134. 
Francavilla, R., Polimeno, L., Demichina, A., Maurogiovanni, G., Principi, B., Scaccianoce, G., 
Ierardi, E., Russo, F., Riezzo, G. & Di Leo, A. (2014). Lactobacillus reuteri Strain 
Combination In Helicobacter pylori Infection: A Randomized, Double-Blind, Placebo-
Controlled Study. Journal of clinical gastroenterology, 48(5), pp. 407-413. 
Frazier, T.H., DiBaise, J.K. & McClain, C.J. (2011). Gut microbiota, intestinal permeability, 
obesity-induced inflammation, and liver injury. Journal of Parenteral and Enteral Nutrition, 
35(5 suppl), pp. 14S-20S. 
Frese, S.A., Benson, A.K., Tannock, G.W., Loach, D.M., Kim, J., Zhang, M., Oh, P.L., Heng, 
N.C., Patil, P.B. & Juge, N. (2011). The evolution of host specialization in the vertebrate gut 
symbiont Lactobacillus reuteri. PLoS genetics, 7(2), p. e1001314. 
Freter, R. (1955). The fatal enteric cholera infection in the guinea pig, achieved by inhibition of 
normal enteric flora. The Journal of infectious diseases, pp. 57-65. 
Furet, J.-P., Kong, L.-C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.-L., Mariat, D., Corthier, 
G., Doré, J. & Henegar, C. (2010). Differential adaptation of human gut microbiota to 
bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation 
markers. Diabetes. 
Gao, K., Liu, L., Dou, X., Wang, C., Liu, J., Zhang, W. & Wang, H. (2016). Doses Lactobacillus 
reuteri depend on adhesive ability to modulate the intestinal immune response and 
metabolism in mice challenged with lipopolysaccharide. Scientific reports, 6, p. 28332. 
Garcia, A.H., Herrmann, A.M. & Håkansson, S. (2017). Isothermal microcalorimetry for rapid 
viability assessment of freeze-dried Lactobacillus reuteri. Process Biochemistry, 55, pp. 49-
54. 
Gerez, C., Cuezzo, S., Rollan, G. & Font de Valdez, G. (2008). Lactobacillus reuteri CRL 1100 
as starter culture for wheat dough fermentation. Food Microbiology, 25(2), pp. 253-259. 
Grande, R., Celia, C., Mincione, G., Stringaro, A., Di Marzio, L., Colone, M., Di Marcantonio, 
M.C., Savino, L., Puca, V. & Santoliquido, R. (2017). Detection and physicochemical 
characterization of membrane vesicles (MVs) of Lactobacillus reuteri DSM 17938. Frontiers 
in microbiology, 8, p. 1040. 
Grasset, E., Pinto, M., Dussaulx, E., Zweibaum, A. & Desjeux, J.F. (1984). Epithelial properties 
of human colonic carcinoma cell line Caco-2: electrical parameters. American Journal of 
Physiology-Cell Physiology, 247(3), pp. C260-C267. 
Grill, J., Cayuela, C., Antoine, J. & Schneider, F. (2000). Isolation and characterization of a 
Lactobacillus amylovorus mutant depleted in conjugated bile salt hydrolase activity: relation 
between activity and bile salt resistance. J Appl Microbiol, 89(4), pp. 553-563. 
Gruner, D., Paris, S. & Schwendicke, F. (2016). Probiotics for managing caries and periodontitis: 
Systematic review and meta-analysis. Journal of dentistry, 48, pp. 16-25. 
Gupta, P., Andrew, H., Kirschner, B.S. & Guandalini, S. (2000). Is Lactobacillus GG helpful in 
children with Crohn’s disease? Results of a preliminary, open-label study. Journal of 
pediatric gastroenterology and nutrition, 31(4), pp. 453-457. 
68 
 
Gutierrez-Castrellon, P., Lopez-Velazquez, G., Diaz-Garcia, L., Jimenez-Gutierrez, C., Mancilla-
Ramirez, J., Estevez-Jimenez, J. & Parra, M. (2014). Diarrhea in preschool children and 
Lactobacillus reuteri: a randomized controlled trial. Pediatrics, 133(4), pp. e904-e909. 
Gänzle, M.G., Höltzel, A., Walter, J., Jung, G. & Hammes, W.P. (2000). Characterization of 
reutericyclin produced by Lactobacillus reuteri LTH2584. Applied and Environmental 
Microbiology, 66(10), pp. 4325-4333. 
Gänzle, M.G. & Vogel, R.F. (2003). Contribution of reutericyclin production to the stable 
persistence of Lactobacillus reuteri in an industrial sourdough fermentation. International 
Journal of Food Microbiology, 80(1), pp. 31-45. 
Hammes, W.P. & Hertel, C. (2006). The genera Lactobacillus and Carnobacterium. In: The 
prokaryotes Springer, pp. 320-403. 
Hatayama, H., Iwashita, J., Kuwajima, A. & Abe, T. (2007). The short chain fatty acid, butyrate, 
stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. 
Biochemical and biophysical research communications, 356(3), pp. 599-603. 
Helander, H.F. & Fändriks, L. (2014). Surface area of the digestive tract – revisited. Scandinavian 
journal of gastroenterology, 49(6), pp. 681-689. 
Hoben, H. & Somasegaran, P. (1982). Comparison of the pour, spread, and drop plate methods 
for enumeration of Rhizobium spp. in inoculants made from presterilized peat. Applied and 
Environmental Microbiology, 44(5), pp. 1246-1247. 
Hofmann, A.F. (1999). The continuing importance of bile acids in liver and intestinal disease. 
Archives of internal medicine, 159(22), pp. 2647-2658. 
Hole, A.S., Rud, I., Grimmer, S., Sigl, S., Narvhus, J. & Sahlstrøm, S. (2012). Improved 
bioavailability of dietary phenolic acids in whole grain barley and oat groat following 
fermentation with probiotic Lactobacillus acidophilus, Lactobacillus johnsonii, and 
Lactobacillus reuteri. J Agric Food Chem, 60(25), pp. 6369-6375. 
Hollander, D. (1999). Intestinal permeability, leaky gut, and intestinal disorders. Current 
gastroenterology reports, 1(5), pp. 410-416. 
Holmes, E., Loo, R.L., Stamler, J., Bictash, M., Yap, I.K., Chan, Q., Ebbels, T., De Iorio, M., 
Brown, I.J. & Veselkov, K.A. (2008). Human metabolic phenotype diversity and its 
association with diet and blood pressure. Nature, 453(7193), pp. 396-400. 
Hooper, L.V. & Gordon, J.I. (2001). Commensal host-bacterial relationships in the gut. Science, 
292(5519), pp. 1115-1118. 
Huang, R. & Hu, J. (2017). Positive effect of probiotics on constipation in children: a systematic 
review and meta-analysis of six randomized controlled trials. Frontiers in cellular and 
infection microbiology, 7, p. 153. 
Huang, R., Ning, H., Yang, L., Jia, C., Yang, F., Xu, G. & Tan, H. (2017). Efficacy of Probiotics 
on Anxiety: A Meta-analysis of Randomized Controlled Trials. Neuropsychiatry, 7(6), pp. 
862-871. 
Huang, R., Wang, K. & Hu, J. (2016). Effect of probiotics on depression: a systematic review and 
meta-analysis of randomized controlled trials. Nutrients, 8(8), p. 483. 
Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J.H., Chinwalla, A.T., Creasy, 
H.H., Earl, A.M., FitzGerald, M.G. & Fulton, R.S. (2012). Structure, function and diversity of 
the healthy human microbiome. Nature, 486(7402), p. 207. 
69 
 
In, Y.W., Kim, J.J., Kim, H.J. & Oh, S.W. (2013). Antimicrobial Activities of Acetic Acid, Citric 
Acid and Lactic Acid against Shigella Species. Journal of Food Safety, 33(1), pp. 79-85. 
Indrio, F., Di Mauro, A., Riezzo, G., Civardi, E., Intini, C., Corvaglia, L., Ballardini, E., 
Bisceglia, M., Cinquetti, M. & Brazzoduro, E. (2014). Prophylactic use of a probiotic in the 
prevention of colic, regurgitation, and functional constipation: A randomized clinical trial. 
JAMA pediatrics, 168(3), pp. 228-233. 
Jacobsen, C.N., Nielsen, V.R., Hayford, A., Møller, P., Michaelsen, K., Paerregaard, A., 
Sandström, B., Tvede, M. & Jakobsen, M. (1999). Screening of probiotic activities of forty-
seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization 
ability of five selected strains in humans. Applied and Environmental Microbiology, 65(11), 
pp. 4949-4956. 
Jenkins, D.J., Kendall, C.W. & Vuksan, V. (1999). Inulin, oligofructose and intestinal function. 
The Journal of nutrition, 129(7), pp. 1431S-1433s. 
Jennings, T.A. (1999). Lyophilization: introduction and basic principles: CRC press. 
Jensen, H., Roos, S., Jonsson, H., Rud, I., Grimmer, S., van Pijkeren, J.-P., Britton, R.A. & 
Axelsson, L. (2014). Role of Lactobacillus reuteri cell and mucus-binding protein A (CmbA) 
in adhesion to intestinal epithelial cells and mucus in vitro. Microbiology, 160(4), pp. 671-
681. 
Jiménez, E., Marín, M.L., Martín, R., Odriozola, J.M., Olivares, M., Xaus, J., Fernández, L. & 
Rodríguez, J.M. (2008). Is meconium from healthy newborns actually sterile? Research in 
Microbiology, 159(3), pp. 187-193. 
Johansson, M.E., Phillipson, M., Petersson, J., Velcich, A., Holm, L. & Hansson, G.C. (2008). 
The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. 
Proceedings of the National Academy of Sciences, 105(39), pp. 15064-15069. 
Johansson, M.L., Molin, G., Pettersson, B., Uhlen, M. & Ahrne, S. (1995). Characterization and 
species recognition of Lactobacillus plantarum strains by restriction fragment length 
polymorphism (RFLP) of the 16S rRNA gene. Journal of applied bacteriology, 79(5), pp. 
536-541. 
Jonsson, H., Ström, E. & Roos, S. (2001). Addition of mucin to the growth medium triggers 
mucus-binding activity in different strains of Lactobacillus reuteri in vitro. FEMS 
Microbiology Letters, 204(1), pp. 19-22. 
Kamiya, T., Wang, L., Forsythe, P., Goettsche, G., Mao, Y., Wang, Y., Tougas, G. & 
Bienenstock, J. (2006). Inhibitory effects of Lactobacillus reuteri on visceral pain induced by 
colorectal distension in Sprague-Dawley rats. Gut, 55(2), pp. 191-196. 
Kandil, H.M., Argenzio, R.A., Chen, W., Berschneider, H.M., Stiles, A.D., Westwick, J.K., 
Rippe, R.A., Brenner, D.A. & Rhoads, J.M. (1995). L-glutamine and L-asparagine stimulate 
ODC activity and proliferation in a porcine jejunal enterocyte line. American Journal of 
Physiology-Gastrointestinal and Liver Physiology, 269(4), pp. G591-G599. 
Kandler, O., Stetter, K.-O. & Köhl, R. (1980). Lactobacillus reuteri sp. nov., a New Species of 
Heterofermentative Lactobacilli. Zentralblatt für Bakteriologie: I. Abt. Originale C: 
Allgemeine, angewandte und ökologische Mikrobiologie, 1(3), pp. 264-269. 
70 
 
Karimi, S., Jonsson, H., Lundh, T. & Roos, S. (2018). Lactobacillus reuteri strains protect 
epithelial barrier integrity of IPEC‐J2 monolayers from the detrimental effect of 
enterotoxigenic Escherichia coli. Physiological reports, 6(2). 
Kinross, J.M., Alkhamesi, N., Barton, R.H., Silk, D.B., Yap, I.K., Darzi, A.W., Holmes, E. & 
Nicholson, J.K. (2010). Global metabolic phenotyping in an experimental laparotomy model 
of surgical trauma. Journal of proteome research, 10(1), pp. 277-287. 
Kirjavainen, P.V., Ouwehand, A.C., Isolauri, E. & Salminen, S.J. (1998). The ability of probiotic 
bacteria to bind to human intestinal mucus. FEMS Microbiology Letters, 167(2), pp. 185-189. 
Koenig, J.E., Spor, A., Scalfone, N., Fricker, A.D., Stombaugh, J., Knight, R., Angenent, L.T. & 
Ley, R.E. (2011). Succession of microbial consortia in the developing infant gut microbiome. 
Proceedings of the National Academy of Sciences, 108(Supplement 1), pp. 4578-4585. 
Kollath, W. (1953). The increase of the diseases of civilization and their prevention. Munchener 
medizinische Wochenschrift (1950), 95(47), p. 1260. 
Kos, B., Šušković, J., Vuković, S., Šimpraga, M., Frece, J. & Matošić, S. (2003). Adhesion and 
aggregation ability of probiotic strain Lactobacillus acidophilus M92. J Appl Microbiol, 
94(6), pp. 981-987. 
Kris-Etherton, P.M., Hecker, K.D., Bonanome, A., Coval, S.M., Binkoski, A.E., Hilpert, K.F., 
Griel, A.E. & Etherton, T.D. (2002). Bioactive compounds in foods: their role in the 
prevention of cardiovascular disease and cancer. The American journal of medicine, 113(9), 
pp. 71-88. 
Krug, S.M., Schulzke, J.D. & Fromm, M. Tight junction, selective permeability, and related 
diseases. In: Proceedings of Seminars in cell & developmental biology2014: Elsevier, pp. 
166-176. 
Kšonžeková, P., Bystrický, P., Vlčková, S., Pätoprstý, V., Pulzová, L., Mudroňová, D., 
Kubašková, T., Csank, T. & Tkáčiková, Ľ. (2016). Exopolysaccharides of Lactobacillus 
reuteri: their influence on adherence of E. coli to epithelial cells and inflammatory response. 
Carbohydrate polymers, 141, pp. 10-19. 
Lamas, B., Richard, M.L., Leducq, V., Pham, H.-P., Michel, M.-L., Da Costa, G., Bridonneau, C., 
Jegou, S., Hoffmann, T.W. & Natividad, J.M. (2016). CARD9 impacts colitis by altering gut 
microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nature 
medicine, 22(6), p. 598. 
Lee, S.H. (2015). Intestinal permeability regulation by tight junction: implication on 
inflammatory bowel diseases. Intestinal research, 13(1), pp. 11-18. 
Lepage, P., Häsler, R., Spehlmann, M.E., Rehman, A., Zvirbliene, A., Begun, A., Ott, S., 
Kupcinskas, L., Doré, J. & Raedler, A. (2011). Twin study indicates loss of interaction 
between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology, 141(1), 
pp. 227-236. 
Li, B., Tian, F., Liu, X., Zhao, J., Zhang, H. & Chen, W. (2011). Effects of cryoprotectants on 
viability of Lactobacillus reuteri CICC6226. Appl Microbiol Biotechnol, 92(3), pp. 609-616. 
Lilly, D.M. & Stillwell, R.H. (1965). Probiotics: growth-promoting factors produced by 
microorganisms. Science, 147(3659), pp. 747-748. 
71 
 
Liu, H.Y., Roos, S., Jonsson, H., Ahl, D., Dicksved, J., Lindberg, J.E. & Lundh, T. (2015). 
Effects of Lactobacillus johnsonii and Lactobacillus reuteri on gut barrier function and heat 
shock proteins in intestinal porcine epithelial cells. Physiological reports, 3(4). 
Lozupone, C.A., Stombaugh, J.I., Gordon, J.I., Jansson, J.K. & Knight, R. (2012). Diversity, 
stability and resilience of the human gut microbiota. Nature, 489(7415), pp. 220-230. 
Lukić, J., Strahinić, I., Jovcić, B., Filipić, B., Topisirović, L., Kojić, M. & Begović, J. (2012). 
Different roles of lactococcal aggregation factor and mucin binding protein in adhesion to 
gastrointestinal mucosa. Applied and Environmental Microbiology, pp. AEM. 02141-12. 
Lund, P., Tramonti, A. & De Biase, D. (2014). Coping with low pH: molecular strategies in 
neutralophilic bacteria. FEMS Microbiology Reviews, 38(6), pp. 1091-1125. 
MacKenzie, D.A., Jeffers, F., Parker, M.L., Vibert-Vallet, A., Bongaerts, R.J., Roos, S., Walter, J. 
& Juge, N. (2010). Strain-specific diversity of mucus-binding proteins in the adhesion and 
aggregation properties of Lactobacillus reuteri. Microbiology, 156(11), pp. 3368-3378. 
Mackie, R.I., Sghir, A. & Gaskins, H.R. (1999). Developmental microbial ecology of the neonatal 
gastrointestinal tract. The American journal of clinical nutrition, 69(5), pp. 1035s-1045s. 
Madara, J. & Pappenheimer, J. (1987). Structural basis for physiological regulation of paracellular 
pathways in intestinal epithelia. The Journal of membrane biology, 100(1), pp. 149-164. 
Marchesi, J.R., Holmes, E., Khan, F., Kochhar, S., Scanlan, P., Shanahan, F., Wilson, I.D. & 
Wang, Y. (2007). Rapid and noninvasive metabonomic characterization of inflammatory 
bowel disease. Journal of proteome research, 6(2), pp. 546-551. 
Martin‐Cabezas, R., Davideau, J.L., Tenenbaum, H. & Huck, O. (2016). Clinical efficacy of 
probiotics as an adjunctive therapy to non‐surgical periodontal treatment of chronic 
periodontitis: a systematic review and meta‐analysis. Journal of clinical periodontology, 
43(6), pp. 520-530. 
Martin, P., Hansen, J., Siadak, A. & Nowinski, R. (1981). Monoclonal antibodies recognizing 
normal human T lymphocytes and malignant human B lymphocytes: a comparative study. 
The Journal of Immunology, 127(5), pp. 1920-1923. 
Martínez, I., Stegen, J.C., Maldonado-Gómez, M.X., Eren, A.M., Siba, P.M., Greenhill, A.R. & 
Walter, J. (2015). The gut microbiota of rural papua new guineans: composition, diversity 
patterns, and ecological processes. Cell reports, 11(4), pp. 527-538. 
Martinsen, T.C., Bergh, K. & Waldum, H.L. (2005). Gastric juice: a barrier against infectious 
diseases. Basic & Clinical Pharmacology & Toxicology, 96(2), pp. 94-102. 
Matsuo, K., Ota, H., Akamatsu, T., Sugiyama, A. & Katsuyama, T. (1997). Histochemistry of the 
surface mucous gel layer of the human colon. Gut, 40(6), pp. 782-789. 
McKean, J., Naug, H., Nikbakht, E., Amiet, B. & Colson, N. (2017). Probiotics and subclinical 
psychological symptoms in healthy participants: a systematic review and meta-analysis. The 
Journal of Alternative and Complementary Medicine, 23(4), pp. 249-258. 
Meng, X., Stanton, C., Fitzgerald, G., Daly, C. & Ross, R. (2008). Anhydrobiotics: The 
challenges of drying probiotic cultures. Food Chem, 106(4), pp. 1406-1416. 
Mercier, C., Durrieu, C., Briandet, R., Domakova, E., Tremblay, J., Buist, G. & Kulakauskas, S. 
(2002). Positive role of peptidoglycan breaks in lactococcal biofilm formation. Molecular 
microbiology, 46(1), pp. 235-243. 
72 
 
Miller, L.E., Ouwehand, A.C. & Ibarra, A. (2017). Effects of probiotic-containing products on 
stool frequency and intestinal transit in constipated adults: systematic review and meta-
analysis of randomized controlled trials. Annals of gastroenterology, 30(6), p. 629. 
Mitsuoka, T. (1992). Intestinal flora and aging. Nutr Rev, 50(12), pp. 438-446. 
Molin, G., Jeppsson, B., Johansson, M.L., Ahrné, S., Nobaek, S., Ståhl, M. & Bengmark, S. 
(1993). Numerical taxonomy of Lactobacillus spp. associated with healthy and diseased 
mucosa of the human intestines. J Appl Microbiol, 74(3), pp. 314-323. 
Mora, D. & Arioli, S. (2014). Microbial urease in health and disease. PLoS pathogens, 10(12), p. 
e1004472. 
Muyzer, G., De Waal, E.C. & Uitterlinden, A.G. (1993). Profiling of complex microbial 
populations by denaturing gradient gel electrophoresis analysis of polymerase chain reaction-
amplified genes coding for 16S rRNA. Applied and Environmental Microbiology, 59(3), pp. 
695-700. 
Nannen, N.L. & Hutkins, R.W. (1991). Proton-Translocating Adenosine Triphosphatase Activity 
in Lactic Acid Bacterial1. Journal of dairy science, 74(3), pp. 747-751. 
Neurath, M.F. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 
14(5), p. 329. 
Nielsen, L.E., Kadavy, D.R., Rajagopal, S., Drijber, R. & Nickerson, K.W. (2005). Survey of 
extreme solvent tolerance in gram-positive cocci: membrane fatty acid changes in 
Staphylococcus haemolyticus grown in toluene. Applied and Environmental Microbiology, 
71(9), pp. 5171-5176. 
O’Toole, P.W. & Jeffery, I.B. (2015). Gut microbiota and aging. Science, 350(6265), pp. 1214-
1215. 
Oh, P.L., Benson, A.K., Peterson, D.A., Patil, P.B., Moriyama, E.N., Roos, S. & Walter, J. 
(2009). Diversification of the gut symbiont Lactobacillus reuteri as a result of host-driven 
evolution. ISME J, 4(3), pp. 377-387. 
Okoli, A.S., Raftery, M.J. & Mendz, G.L. (2012). Effects of human and porcine bile on the 
proteome of Helicobacter hepaticus. Proteome science, 10(1), p. 27. 
Okoli, A.S., Wilkins, M.R., Raftery, M.J. & Mendz, G.L. (2010). Response of Helicobacter 
hepaticus to bovine bile. Journal of proteome research, 9(3), pp. 1374-1384. 
Oliva, S., Di Nardo, G., Ferrari, F., Mallardo, S., Rossi, P., Patrizi, G., Cucchiara, S. & Stronati, 
L. (2012). Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 
rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther, 35(3), 
pp. 327-334. 
Ortiz-Lucas, M., Tobias, A., Saz, P. & Sebastián, J.J. (2013). Effect of probiotic species on 
irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig, 
105, pp. 19-36. 
Pallin, A., Agback, P., Jonsson, H. & Roos, S. (2016). Evaluation of growth, metabolism and 
production of potentially bioactive components during fermentation of barley with 
Lactobacillus reuteri. Food Microbiology, 57, pp. 159-171. 
Palmer, C., Bik, E.M., DiGiulio, D.B., Relman, D.A. & Brown, P.O. (2007). Development of the 
human infant intestinal microbiota. PLoS biology, 5(7), p. e177. 
73 
 
Paul, S., Alegre, K.O., Holdsworth, S.R., Rice, M., Brown, J.A., McVeigh, P., Kelly, S.M. & 
Law, C.J. (2014). A single‐component multidrug transporter of the major facilitator 
superfamily is part of a network that protects Escherichia coli from bile salt stress. Molecular 
microbiology, 92(4), pp. 872-884. 
Pearson, A., Eastham, E., Laker, M., Craft, A. & Nelson, R. (1982). Intestinal permeability in 
children with Crohn's disease and coeliac disease. British medical journal (Clinical research 
ed.), 285(6334), p. 20. 
Pecze, L., Blum, W. & Schwaller, B. (2013). Mechanism of capsaicin receptor TRPV1-mediated 
toxicity in pain-sensing neurons focusing on the effects of Na+/Ca 2+ fluxes and the Ca 2+-
binding protein calretinin. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 
1833(7), pp. 1680-1691. 
Pepi, M., Heipieper, H.J., Fischer, J., Ruta, M., Volterrani, M. & Focardi, S.E. (2008). Membrane 
fatty acids adaptive profile in the simultaneous presence of arsenic and toluene in Bacillus sp. 
ORAs2 and Pseudomonas sp. ORAs5 strains. Extremophiles, 12(3), pp. 343-349. 
Perez-Muñoz, M.E., Arrieta, M.-C., Ramer-Tait, A.E. & Walter, J. (2017). A critical assessment 
of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the 
pioneer infant microbiome. Microbiome, 5(1), p. 48. 
Perez‐Burgos, A., Wang, L., McVey Neufeld, K.A., Mao, Y.K., Ahmadzai, M., Janssen, L.J., 
Stanisz, A.M., Bienenstock, J. & Kunze, W.A. (2015). The TRPV1 channel in rodents is a 
major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. The 
Journal of physiology, 593(17), pp. 3943-3957. 
Porayath, C., Suresh, M.K., Biswas, R., Nair, B.G., Mishra, N. & Pal, S. (2018). Autolysin 
mediated adherence of Staphylococcus aureus with Fibronectin, Gelatin and Heparin. 
International journal of biological macromolecules, 110, pp. 179-184. 
Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, T., Pons, N., 
Levenez, F. & Yamada, T. (2010). A human gut microbial gene catalogue established by 
metagenomic sequencing. Nature, 464(7285), p. 59. 
Rajilić-Stojanović, M., Heilig, H.G.H.J., Tims, S., Zoetendal, E.G. & de Vos, W.M. (2013). 
Long-term monitoring of the human intestinal microbiota composition. Environmental 
Microbiology, 15(4), pp. 1146-1159. 
Rajilić-Stojanović, M., Smidt, H. & De Vos, W.M. (2007). Diversity of the human 
gastrointestinal tract microbiota revisited. Environmental Microbiology, 9(9), pp. 2125-2136. 
Rault, A., Béal, C., Ghorbal, S., Ogier, J.-C. & Bouix, M. (2007). Multiparametric flow cytometry 
allows rapid assessment and comparison of lactic acid bacteria viability after freezing and 
during frozen storage. Cryobiology, 55(1), pp. 35-43. 
Rinkinen, M., Westermarck, E., Salminen, S. & Ouwehand, A.C. (2003). Absence of host 
specificity for in vitro adhesion of probiotic lactic acid bacteria to intestinal mucus. Vet 
Microbiol, 97(1-2), pp. 55-61. 
Roos, S. & Jonsson, H. (2002). A high-molecular-mass cell-surface protein from Lactobacillus 
reuteri 1063 adheres to mucus components. Microbiology, 148(2), pp. 433-442. 
Rosander, A., Connolly, E. & Roos, S. (2008). Removal of antibiotic resistance gene-carrying 
plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting 
74 
 
daughter strain, L. reuteri DSM 17938. Applied and Environmental Microbiology, 74(19), pp. 
6032-6040. 
Roselli, M., Finamore, A., Britti, M.S., Konstantinov, S.R., Smidt, H., de Vos, W.M. & 
Mengheri, E. (2007). The novel porcine Lactobacillus sobrius strain protects intestinal cells 
from enterotoxigenic Escherichia coli K88 infection and prevents membrane barrier damage. 
The Journal of nutrition, 137(12), pp. 2709-2716. 
Rosenfeldt, V., Benfeldt, E., Valerius, N.H., Pærregaard, A. & Michaelsen, K.F. (2004). Effect of 
probiotics on gastrointestinal symptoms and small intestinal permeability in children with 
atopic dermatitis. The Journal of pediatrics, 145(5), pp. 612-616. 
Santivarangkna, C., Higl, B. & Foerst, P. (2008). Protection mechanisms of sugars during 
different stages of preparation process of dried lactic acid starter cultures. Food Microbiology, 
25(3), pp. 429-441. 
Sartor, R.B. (2008). Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology, 
134(2), pp. 577-594. 
Saulnier, D.M., Santos, F., Roos, S., Mistretta, T.-A., Spinler, J.K., Molenaar, D., Teusink, B. & 
Versalovic, J. (2011). Exploring metabolic pathway reconstruction and genome-wide 
expression profiling in Lactobacillus reuteri to define functional probiotic features. PloS one, 
6(4), p. e18783. 
Saura-Calixto, F. (2010). Dietary fiber as a carrier of dietary antioxidants: an essential 
physiological function. J Agric Food Chem, 59(1), pp. 43-49. 
Savage, D.C. (1977). Microbial ecology of the gastrointestinal tract. Annual Reviews in 
Microbiology, 31(1), pp. 107-133. 
Sawicki, R. (2017). Inverse correlation between freeze-thaw survival and storage stability of 
freeze-dried Lactobacillus reuteri DSM 17938 and a microcalorimetric search for GASP. 
Savino, F., Cordisco, L., Tarasco, V., Palumeri, E., Calabrese, R., Oggero, R., Roos, S. & 
Matteuzzi, D. (2010). Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, 
double-blind, placebo-controlled trial. Pediatrics, 126(3), pp. e526-e533. 
Schaefer, L., Auchtung, T.A., Hermans, K.E., Whitehead, D., Borhan, B. & Britton, R.A. (2010). 
The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress 
via interaction with thiol groups. Microbiology, 156(6), pp. 1589-1599. 
Schierack, P., Nordhoff, M., Pollmann, M., Weyrauch, K.D., Amasheh, S., Lodemann, U., Jores, 
J., Tachu, B., Kleta, S. & Blikslager, A. (2006). Characterization of a porcine intestinal 
epithelial cell line for in vitro studies of microbial pathogenesis in swine. Histochemistry and 
cell biology, 125(3), pp. 293-305. 
Schoug, Å. (2009). A dry phase of life2009). 
Schreck Bird, A., Gregory, P.J., Jalloh, M.A., Risoldi Cochrane, Z. & Hein, D.J. (2017). 
Probiotics for the treatment of infantile colic: a systematic review. Journal of pharmacy 
practice, 30(3), pp. 366-374. 
Schrezenmeir, J. & de Vrese, M. (2001). Probiotics, prebiotics, and synbiotics—approaching a 
definition. The American journal of clinical nutrition, 73(2), pp. 361s-364s. 
Sender, R., Fuchs, S. & Milo, R. (2016). Revised estimates for the number of human and bacteria 
cells in the body. PLoS biology, 14(8), p. e1002533. 
75 
 
Shao, Y., Wang, Z., Bao, Q. & Zhang, H. (2016). Application of propidium monoazide 
quantitative real-time PCR to quantify the viability of Lactobacillus delbrueckii ssp. 
bulgaricus. Journal of dairy science, 99(12), pp. 9570-9580. 
Shen, N.T., Maw, A., Tmanova, L.L., Pino, A., Ancy, K., Crawford, C.V., Simon, M.S. & Evans, 
A.T. (2017). Timely use of probiotics in hospitalized adults prevents Clostridium difficile 
infection: a systematic review with meta-regression analysis. Gastroenterology, 152(8), pp. 
1889-1900. e9. 
Sicard, J.-F., Le Bihan, G., Vogeleer, P., Jacques, M. & Harel, J. (2017). Interactions of intestinal 
bacteria with components of the intestinal mucus. Frontiers in cellular and infection 
microbiology, 7, p. 387. 
Sommer, F., Anderson, J.M., Bharti, R., Raes, J. & Rosenstiel, P. (2017). The resilience of the 
intestinal microbiota influences health and disease. Nature Reviews Microbiology, 15(10), p. 
630. 
Song, Y.-L., Kato, N., Liu, C.-X., Matsumiya, Y., Kato, H. & Watanabe, K. (2000). Rapid 
identification of 11 human intestinal Lactobacillus species by multiplex PCR assays using 
group-and species-specific primers derived from the 16S–23S rRNA intergenic spacer region 
and its flanking 23S rRNA. FEMS Microbiology Letters, 187(2), pp. 167-173. 
Spiller, R., Jenkins, D., Thornley, J., Hebden, J., Wright, T., Skinner, M. & Neal, K. (2000). 
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut 
permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel 
syndrome. Gut, 47(6), pp. 804-811. 
Spinler, J.K., Sontakke, A., Hollister, E.B., Venable, S.F., Oh, P.L., Balderas, M.A., Saulnier, 
D.M., Mistretta, T.-A., Devaraj, S. & Walter, J. (2014). From prediction to function using 
evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse 
probiotic functions. Genome biology and evolution, 6(7), pp. 1772-1789. 
Spinler, J.K., Taweechotipatr, M., Rognerud, C.L., Ou, C.N., Tumwasorn, S. & Versalovic, J. 
(2008). Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities 
targeting diverse enteric bacterial pathogens. Anaerobe, 14(3), pp. 166-171. 
Sriramulu, D.D., Liang, M., Hernandez-Romero, D., Raux-Deery, E., Lünsdorf, H., Parsons, J.B., 
Warren, M.J. & Prentice, M.B. (2008). Lactobacillus reuteri DSM 20016 produces 
cobalamin-dependent diol dehydratase in metabolosomes and metabolizes 1, 2-propanediol 
by disproportionation. J Bacteriol, 190(13), pp. 4559-4567. 
Stolz, P., Vogel, R.F. & Hammes, W.P. (1995). Utilization of electron acceptors by lactobacilli 
isolated from sourdough. Zeitschrift für Lebensmittel-Untersuchung und Forschung, 201(4), 
pp. 402-410. 
Stratiki, Z., Costalos, C., Sevastiadou, S., Kastanidou, O., Skouroliakou, M., Giakoumatou, A. & 
Petrohilou, V. (2007). The effect of a bifidobacter supplemented bovine milk on intestinal 
permeability of preterm infants. Early Human Development, 83(9), pp. 575-579. 
Stromeck, A., Hu, Y., Chen, L. & Gänzle, M.G. (2011). Proteolysis and bioconversion of cereal 
proteins to glutamate and γ-aminobutyrate (GABA) in rye malt sourdoughs. J Agric Food 
Chem, 59(4), pp. 1392-1399. 
76 
 
Su, M.S.-W., Oh, P.L., Walter, J. & Gänzle, M.G. (2012). Intestinal origin of sourdough 
Lactobacillus reuteri isolates as revealed by phylogenetic, genetic, and physiological 
analysis. Applied and Environmental Microbiology, 78(18), pp. 6777-6780. 
Sung, V., D’Amico, F., Cabana, M.D., Chau, K., Koren, G., Savino, F., Szajewska, H., 
Deshpande, G., Dupont, C. & Indrio, F. (2017). Lactobacillus reuteri to treat infant colic: a 
meta-analysis. Pediatrics, p. e20171811. 
Swidsinski, A., Loening-Baucke, V., Theissig, F., Engelhardt, H., Bengmark, S., Koch, S., Lochs, 
H. & Dörffel, Y. (2007). Comparative study of the intestinal mucus barrier in normal and 
inflamed colon. Gut, 56(3), pp. 343-350. 
Szajewska, H., Gyrczuk, E. & Horvath, A. (2013). Lactobacillus reuteri DSM 17938 for the 
management of infantile colic in breastfed infants: a randomized, double-blind, placebo-
controlled trial. The Journal of pediatrics, 162(2), pp. 257-262. 
Söderlind, O., Möllby, R. & Wadström, T. (1973). Purification and some properties of a heat-
labile enterotoxin from Escherichia coli. Zentralblatt fur Bakteriologie, Parasitenkunde, 
Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische 
Mikrobiologie und Parasitologie, 229(2), pp. 190-204. 
Tanaka, H., Doesburg, K., Iwasaki, T. & Mierau, I. (1999). Screening of lactic acid bacteria for 
bile salt hydrolase activity. Journal of dairy science, 82(12), pp. 2530-2535. 
Tannock, G.W., Dashkevicz, M.P. & Feighner, S.D. (1989). Lactobacilli and bile salt hydrolase in 
the murine intestinal tract. Applied and Environmental Microbiology, 55(7), pp. 1848-1851. 
Taranto, M., Sesma, F., de Ruiz Holgado, A.P. & de Valdez, G.F. (1997). Bile salts hydrolase 
plays a key role on cholesterol removal by Lactobacillus reuteri. Biotechnology Letters, 
19(9), pp. 845-847. 
Taranto, M.P., Vera, J.L., Hugenholtz, J., De Valdez, G.F. & Sesma, F. (2003). Lactobacillus 
reuteri CRL1098 produces cobalamin. J Bacteriol, 185(18), pp. 5643-5647. 
Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K. & Ostatnikova, D. 
(2015). Gastrointestinal microbiota in children with autism in Slovakia. Physiology & 
behavior, 138, pp. 179-187. 
Tong, J., Ran, Z., Shen, J., Zhang, C. & Xiao, S. (2007). Meta‐analysis: the effect of 
supplementation with probiotics on eradication rates and adverse events during Helicobacter 
pylori eradication therapy. Aliment Pharmacol Ther, 25(2), pp. 155-168. 
Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, 
M.L., Jones, W.J., Roe, B.A. & Affourtit, J.P. (2009). A core gut microbiome in obese and 
lean twins. Nature, 457(7228), p. 480. 
Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R. & Gordon, J.I. (2006). 
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 
444(7122), pp. 1027-131. 
Ukabam, S., Clamp, J. & Cooper, B. (1983). Abnormal small intestinal permeability to sugars in 
patients with Crohn’s disease of the terminal ileum and colon. Digestion, 27(2), pp. 70-74. 
Ukabam, S. & Cooper, B. (1984). Small intestinal permeability to mannitol, lactulose, and 
polyethylene glycol 400 in celiac disease. Digestive Diseases and Sciences, 29(9), pp. 809-
816. 
77 
 
Urbańska, M., Gieruszczak‐Białek, D. & Szajewska, H. (2016). Systematic review with meta‐
analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Aliment 
Pharmacol Ther, 43(10), pp. 1025-1034. 
Wadstroum, T., Andersson, K., Sydow, M., Axelsson, L., Lindgren, S. & Gullmar, B. (1987a). 
Surface properties of lactobacilli isolated from the small intestine of pigs. Journal of applied 
bacteriology, 62(6), pp. 513-520. 
Wadstroum, T., Andersson, K., Sydow, M., Axelsson, L., Lindgren, S. & Gullmar, B. (1987b). 
Surface properties of lactobacilli isolated from the small intestine of pigs. J Appl Microbiol, 
62(6), pp. 513-520. 
Valeur, N., Engel, P., Carbajal, N., Connolly, E. & Ladefoged, K. (2004). Colonization and 
immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. 
Applied and Environmental Microbiology, 70(2), pp. 1176-1181. 
Walker, R., Clemente, J., Peter, I. & Loos, R. (2017). The prenatal gut microbiome: are we 
colonized with bacteria in utero? Pediatric obesity. 
Walter, J., Britton, R.A. & Roos, S. (2011). Host-microbial symbiosis in the vertebrate 
gastrointestinal tract and the Lactobacillus reuteri paradigm. Proceedings of the National 
Academy of Sciences, 108(Supplement 1), pp. 4645-4652. 
van de Guchte, M., Serror, P., Chervaux, C., Smokvina, T., Ehrlich, S.D. & Maguin, E. (2002). 
Stress responses in lactic acid bacteria. In: Lactic Acid Bacteria: Genetics, Metabolism and 
Applications Springer, pp. 187-216. 
Van Tassell, M.L. & Miller, M.J. (2011). Lactobacillus adhesion to mucus. Nutrients, 3(5), pp. 
613-636. 
Wang, F., Feng, J., Chen, P., Liu, X., Ma, M., Zhou, R., Chang, Y., Liu, J., Li, J. & Zhao, Q. 
(2017). Probiotics in Helicobacter pylori eradication therapy: systematic review and network 
meta-analysis. Clinics and research in hepatology and gastroenterology, 41(4), pp. 466-475. 
Wang, X., Soltesz, V., Molin, G. & Andersson, R. (1995). The role of oral administration of 
oatmeal fermented by Lactobacillus reuteri R2LC on bacterial translocation after acute liver 
failure induced by subtotal liver resection in the rat. Scandinavian journal of 
gastroenterology, 30(2), pp. 180-185. 
Weizman, Z., Abu-Abed, J. & Binsztok, M. (2016). Lactobacillus reuteri DSM 17938 for the 
management of functional abdominal pain in childhood: a randomized, double-blind, placebo-
controlled trial. The Journal of pediatrics, 174, pp. 160-164. e1. 
Weizman, Z., Asli, G. & Alsheikh, A. (2005). Effect of a probiotic infant formula on infections in 
child care centers: comparison of two probiotic agents. Pediatrics, 115(1), pp. 5-9. 
Versalovic, J., Schneider, M., De Bruijn, F.J. & Lupski, J.R. (1994). Genomic fingerprinting of 
bacteria using repetitive sequence-based polymerase chain reaction. Methods in molecular 
and cellular biology, 5(1), pp. 25-40. 
Wessman, P., Håkansson, S., Leifer, K. & Rubino, S. (2013). Formulations for freeze-drying of 
bacteria and their influence on cell survival. Journal of visualized experiments: JoVE(78). 
Vestman, N.R., Hasslöf, P., Keller, M.K., Granström, E., Roos, S., Twetman, S. & Stecksén-
Blicks, C. (2013). Lactobacillus reuteri influences regrowth of mutans streptococci after full-
mouth disinfection: a double-blind, randomised controlled trial. Caries research, 47(4), pp. 
338-345. 
78 
 
Whitehead, K., Versalovic, J., Roos, S. & Britton, R.A. (2008). Genomic and genetic 
characterization of the bile stress response of probiotic Lactobacillus reuteri ATCC 55730. 
Applied and Environmental Microbiology, 74(6), pp. 1812-1819. 
Williams, T.I., Combs, J.C., Lynn, B.C. & Strobel, H.J. (2007). Proteomic profile changes in 
membranes of ethanol-tolerant Clostridium thermocellum. Appl Microbiol Biotechnol, 74(2), 
pp. 422-432. 
VIZOSO PINTO, M.G., Schuster, T., Briviba, K., Watzl, B., Holzapfel, W.H. & Franz, C.M. 
(2007). Adhesive and chemokine stimulatory properties of potentially probiotic Lactobacillus 
strains. Journal of food protection, 70(1), pp. 125-134. 
Vogel, R.F., BöCKER, G., Stolz, P., Ehrmann, M., Fanta, D., Ludwig, W., Pot, B., Kersters, K., 
SCHLEIFER, K.H. & Hammes, W.P. (1994). Identification of lactobacilli from sourdough 
and description of Lactobacillus pontis sp. nov. International Journal of Systematic and 
Evolutionary Microbiology, 44(2), pp. 223-229. 
Vogel, R.F., Knorr, R., Müller, M.R., Steudel, U., Gänzle, M.G. & Ehrmann, M.A. (1999). Non-
dairy lactic fermentations: the cereal world. Antonie Van Leeuwenhoek, 76(1-4), pp. 403-411. 
Vollmer, W., Joris, B., Charlier, P. & Foster, S. (2008). Bacterial peptidoglycan (murein) 
hydrolases. FEMS Microbiology Reviews, 32(2), pp. 259-286. 
Wu, R., Pasyk, M., Wang, B., Forsythe, P., Bienenstock, J., Mao, Y.K., Sharma, P., Stanisz, A. & 
Kunze, W. (2013). Spatiotemporal maps reveal regional differences in the effects on gut 
motility for Lactobacillus reuteri and rhamnosus strains. Neurogastroenterology & Motility, 
25(3). 
Yang, X., Teng, K., Zhang, J., Wang, F., Zhang, T., Ai, G., Han, P., Bai, F. & Zhong, J. (2017). 
Transcriptome responses of Lactobacillus acetotolerans F28 to a short and long term ethanol 
stress. Scientific reports, 7(1), p. 2650. 
Yatsunenko, T., Rey, F.E., Manary, M.J., Trehan, I., Dominguez-Bello, M.G., Contreras, M., 
Magris, M., Hidalgo, G., Baldassano, R.N. & Anokhin, A.P. (2012). Human gut microbiome 
viewed across age and geography. Nature, 486(7402), p. 222. 
Yuan, F., Ni, H., Asche, C.V., Kim, M., Walayat, S. & Ren, J. (2017). Efficacy of 
Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. 
Current medical research and opinion, 33(7), pp. 1191-1197. 
Zajac, A.E., Adams, A.S. & Turner, J.H. A systematic review and meta‐analysis of probiotics for 
the treatment of allergic rhinitis. In: Proceedings of International forum of allergy & 
rhinology2015: Wiley Online Library, pp. 524-532. 
Zelante, T., Iannitti, R.G., Cunha, C., De Luca, A., Giovannini, G., Pieraccini, G., Zecchi, R., 
D’angelo, C., Massi-Benedetti, C. & Fallarino, F. (2013). Tryptophan catabolites from 
microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-
22. Immunity, 39(2), pp. 372-385. 
Zhang, Y.-M. & Rock, C.O. (2008). Membrane lipid homeostasis in bacteria. Nature Reviews 
Microbiology, 6(3), p. 222. 
Zheng, J., Zhao, X., Lin, X.B. & Gänzle, M. (2015). Comparative genomics Lactobacillus reuteri 
from sourdough reveals adaptation of an intestinal symbiont to food fermentations. Scientific 
reports, 5, p. 18234. 
79 
 
Zhou, Q., Zhang, B. & Nicholas Verne, G. (2009). Intestinal membrane permeability and 
hypersensitivity in the irritable bowel syndrome. Pain, 146(1), pp. 41-46. 
Zhou, Z., White, K.A., Polissi, A., Georgopoulos, C. & Raetz, C.R. (1998). Function of 
Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid 
biosynthesis. Journal of Biological Chemistry, 273(20), pp. 12466-12475. 
Zuccotti, G., Meneghin, F., Aceti, A., Barone, G., Callegari, M.L., Di Mauro, A., Fantini, M., 
Gori, D., Indrio, F. & Maggio, L. (2015). Probiotics for prevention of atopic diseases in 
infants: systematic review and meta‐analysis. Allergy, 70(11), pp. 1356-1371. 
Årsköld, E., Lohmeier-Vogel, E., Cao, R., Roos, S., Rådström, P. & van Niel, E.W. (2008). 
Phosphoketolase pathway dominates in Lactobacillus reuteri ATCC 55730 containing dual 
pathways for glycolysis. J Bacteriol, 190(1), pp. 206-212. 
  
80 
 
 
 
 
81 
 
Probiotics are live microorganisms which, when eaten in sufficient quantities, 
give a positive health effect. Most of the probiotic products on the market contain 
lactic acid bacteria. Lactobacillus reuteri is a species belonging to this group of 
bacteria. It occurs naturally in the intestine of birds and mammals. In humans, it 
is often found in the mouth, gastrointestinal tract, breast milk and the vagina. It 
was once prevalent in the gut of most humans, but because of lifestyle changes 
it has become rarer. Nowadays, it can be found in a range of different probiotic 
products and is one of the most clinically studied probiotic bacteria in the world. 
As a probiotic supplement, it has been shown to help against a number of 
different diseases and disorders. The best effects have been seen in infantile 
colic, but it has also been shown to alleviate diarrhoea and intestinal pain in both 
children and adults. As the name indicates, the lactic acid bacteria produce lactic 
acid, but they also produce a range of other compounds with biological activity 
and hence have a positive health effect. These include vitamins and other 
antioxidants, which can also be found in fruits, vegetables and whole grain 
products, but also compounds produced by the microorganisms in the human 
gastrointestinal tract.  
The starting point for L. reuteri as a probiotic bacteria was when scientists in 
the 1980s showed that it could produce an antimicrobial compound, which was 
given the name reuterin. Since then, studies have shown that it can produce a 
number of other biologically active compounds. When L. reuteri is used to 
ferment whole grain flour, it can produce e.g. antioxidants (polyphenols) and 
antimicrobial substances. Cereals are a good substrate for cultivating L. reuteri, 
and sourdoughs are actually the only environment outside the body of animals 
and humans where it has been isolated. The first part of this thesis investigated 
whether different strains of L. reuteri produce bioactive compounds during 
fermentation of whole grain barley flour. The results showed that the fermented 
barley contained a number of different biologically active compounds, e.g. 
gamma-aminobutyric acid (GABA), which is a signal substance in the central 
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nervous system, but also indole-3-aldehyde, serotonin and tryptamine, which are 
derived from the essential amino acid tryptophan and are all highly interesting 
bioactive compounds. Indole-3-aldehyde and tryptamine activate specific 
receptors (aryl hydrocarbon receptors, AhR) which are involved in the innate 
immune response. Serotonin and GABA are involved in the central nervous 
system. These compounds were already present in the flour before the 
fermentation, but the amount was increased during fermentation by L. reuteri.  
In order for probiotic bacteria such as L. reuteri to have a positive health 
effect through e.g. the production of bioactive compounds, they need to survive 
different kinds of stressful situations. First of all, they need to survive the 
industrial production process and have a long shelf-life. Bacteria used in 
probiotic products are often freeze-dried so that they can be stored during a long 
period in a sort of hibernation state, before coming to life following 
consumption. Freeze-drying is a tough process and up to half of the bacterial 
cells can die even when the process is optimised. In an attempt to increase the 
survival ability of a L. reuteri strain called DSM 17938 (Protectis) during and 
after freeze-drying, the bacteria were subjected to repeated cycles of freezing 
and thawing. By isolating bacteria that survived, variants that could tolerate the 
freeze-thaw stress up to 10 times better than the original strain were found. 
However, there were no indications that the new variants could tolerate freeze-
drying better than the original strain.  
Having survived the stress during industrial production, the bacteria then 
need to survive the harsh environment of the gastrointestinal tract. Strain DSM 
17938 has been shown to tolerate the acidic conditions of the stomach, but it is 
more sensitive to bile than other strains of L. reuteri. The function of bile is to 
dissolve fats in the diet, but it also has an inhibitory effect on many bacteria. To 
protect themselves, certain bacteria have developed strategies involving e.g. 
breaking down the bile, covering themselves in a protective layer or pumping 
the bile out from the cells. By exposing the bacteria to bile, new variants with 
almost 1000-fold better tolerance to bile were isolated.  
A third property considered important for probiotic bacteria is binding to the 
mucus layer within the small and large intestine. The mucus layer acts as a 
physical barrier to prevent harmful bacteria from coming into contact with the 
intestinal cells and going on to enter the body. To remain in place long enough 
to communicate with e.g. immune cells, and thereby have a health-promoting 
effect, probiotic bacteria need to be able to bind to the mucus layer. While DSM 
17938 is an effective probiotic bacterium, it is relatively bad at binding to 
intestinal mucus. Using a method for selecting bacteria with a higher binding 
capacity, new variants with a 10-fold increase in mucus binding capacity were 
isolated.  
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In order to find out whether bacteria are good probiotic candidates, they first 
need to be evaluated using different kinds of cell models before being tested in 
clinical studies. Strain DSM 17938 has previously been shown to have a good 
effect in a number of different cell models. These include a model with intestinal 
epithelial cells which are used to simulate a leaky gut, but also a model with cells 
that express receptors involved in pain perception in the intestine. The new 
variants of DSM 17938 were tested in these two models and the inhibitory effect 
on increased intestinal leakage and increased activation of the pain receptors was 
compared with that of the original strain. All variants tested had a similar effect 
on activation of the pain receptors, but some seemed to have lost the protective 
effect against a leaky gut.  
In conclusion, a number of variants of L. reuteri DSM 17938 with increased 
stress tolerance and mucus binding capacity were successfully isolated. To better 
understand how these improved properties can affect the probiotic effect, further 
evaluations in more complex models and in clinical studies are needed. 
However, the variants of DSM 17938 isolated in this thesis can be a good help 
in understanding what is required of a bacteria to have a good health effect. 
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Probiotika är levande mikroorganismer som när man äter dem i tillräcklig mängd 
ger en positiv effekt på hälsan. De flesta probiotiska produkterna som finns på 
marknaden innehåller mjölksyrabakterier och Lactobacillus reuteri är en art som 
tillhör denna grupp av bakterier. Arten finns naturligt i tarmen hos både fåglar 
och däggdjur. Hos människor finns den ofta i munnen, mag- och tarmsystemet, 
bröstmjölk samt i vaginan. Tidigare förekom den troligtvis hos nästan alla 
människor, men på grund av en ändrad livsstil har den blivit allt mer sällsynt. 
Numera finns den dock i en rad probiotiska produkter och är en av de mest 
kliniskt studerade probiotiska bakterierna i världen. Som ett probiotiskt tillskott 
har L. reuteri visat sig kunna minska problemen med olika sjukdomar och 
funktionella störningar. De bästa effekterna har man sett på spädbarn med kolik, 
men den har även visat sig kunna lindra diarré och magsmärta på både barn och 
vuxna.  
Som namnet mjölksyrabakterier indikerar bildar dessa bakterier mjölksyra, 
men dessutom bildar de en rad andra ämnen som har en biologisk aktivitet och 
därmed en positiv påverkan på hälsan. Det kan till exempel vara vitaminer och 
antioxidanter som finns i frukt, grönsaker och fullkornsprodukter, men det kan 
också vara ämnen som produceras av mikroorganismer i vårt tarmsystem. 
Startskottet för användandet av L. reuteri som probiotisk bakterie var när 
forskare på 1980-talet visade att den kunde producera en antimikrobiell substans 
som gavs namnet reuterin. Sedan dess har studier visat att den kan bilda en rad 
andra biologiskt aktiva ämnen. När bakterien fermenterar fullkornsmjöl har man 
sett att den kan bilda bl.a. antioxidanter (polyfenoler) och antimikrobiella 
substanser. Spannmål fungerar bra för att odla L. reuteri, och surdeg är faktiskt 
den enda miljön utanför kroppen på djur och människor som bakterien har 
isolerats från. I den första delen av denna avhandling undersöktes om olika 
stammar av L. reuteri bildar biologiskt aktiva ämnen vid fermentering av 
fullkornsmjöl av korn. Det visade sig att fermenterat korn innehöll en rad olika 
biologiskt aktiva ämnen, bl.a. gammaaminosmörsyra (GABA) som är en 
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signalsubstans i det centrala nervsystemet, men också indol-3-aldehyd, serotonin 
och tryptamin som bildas från aminosyran tryptofan och som alla är mycket 
intressanta biologiskt aktiva ämnen. Indol-3-aldehyd och tryptamin aktiverar 
speciella receptorer (AhR, aryl hydrocarbon receptor) som är inblandade i 
aktivering av det ospecifika immunförsvaret. Serotonin, likt GABA, är även den 
involverad i det centrala nervsystemet. Ämnena kunde hittas i mjölet innan 
fermenteringen, men mängden av dem ökade vid fermentering med L. reuteri.  
För att probiotiska bakterier som reuteri ska kunna ha en positiv effekt på 
hälsan genom bl.a. bildandet av biologiskt aktiva ämnen, måste de överleva olika 
typer av stress. De måste först och främst överleva den industriella produktionen 
och helst ha en så lång hållbarhet som möjligt. Bakterier som används i 
probiotiska produkter är ofta frystorkade för att kunna förvaras under en lång tid 
i ett slags vilande tillstånd, och sedan väckas upp när de konsumeras. 
Frystorkning är en tuff process och även om den är optimerad kan uppåt hälften 
av bakterierna dö. I ett försök att förbättra överlevnaden vid och efter 
frystorkning hos en stam av L. reuteri kallad DSM 17938 eller Protectis, utsattes 
bakterien för upprepade infrysningar och efterföljande tining. Genom att isolera 
de bakterier som överlevde hittades bakterier som tålde frys-tina-stressen upp 
till tio gånger bättre än ursprungsstammen. Dock kunde man inte se att den nya 
varianten kunde klara frystorkning bättre än den ursprungliga stammen.  
Men det är inte bara viktigt att den ska överleva stressen vid den industriella 
produktionen utan bakterien måste även överleva i den hårda miljön i mag- och 
tarmkanalen. DSM 17938 har visat sig tåla de sura förhållandena i magsäcken 
bra, men studier har visat att den i vissa fall är mer känslig för galla jämfört med 
andra stammar av L. reuteri. Galla har som funktion att lösa upp fett i vår kost 
men har även en hämmande effekt på många bakterier. För att skydda sig har 
vissa bakterier utvecklat strategier för att bryta ner gallan, täcka sig med ett 
skyddande lager, eller aktivt pumpa ut gallan från cellen. Genom att utsätta 
bakterien för galla kunde nya varianter med nästan 1000 gånger bättre tålighet 
mot galla isoleras. En tredje egenskap hos probiotiska bakterier som anses vara 
viktig, är inbindning till slemhinnorna i tunn- och tjocktarm. Dessa slemhinnor 
agerar som en fysisk barriär för att förhindra skadliga bakterier från att nå 
tarmcellerna och ta sig vidare in i kroppen. För att stanna kvar tillräckligt länge 
och kommunicera med bl.a. immunceller och därmed ha en effekt på hälsan, 
måste de probiotiska bakterierna kunna binda till slemhinnorna. Trots att DSM 
17938 är en effektiv probiotisk bakterie är den relativt dålig på att binda till 
slemhinnor. Med en metod för att selektera fram bakterier med högre bindande 
förmåga kunde nya varianter med tio gånger högre bindningsförmåga isoleras.  
För att identifiera lovande probiotiska kandidater, brukar de först utvärderas 
m.h.a. olika typer av cellmodeller, innan de testas i kliniska försök. DSM 17938 
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har tidigare visat sig ha bra effekt i en rad olika typer av cellmodeller, bl.a. i en 
modell med tarmepitelceller där en läckande tarm simuleras, men också i en 
modell med celler som uttrycker receptorer som är involverade i 
smärtupplevelsen i tarmen. De nya varianterna av DSM 17938 testades i dessa 
två modeller och den inhiberande effekten på ökande läckage och ökad 
aktivering av smärtreceptorer jämfördes med den ursprungliga stammen. 
Samtliga varianter som testades hade liknande inhiberande effekt på aktivering 
av smärtreceptorerna. Dock verkade vissa varianter ha tappat den skyddande 
effekten mot en läckande tarm. Sammanfattningsvis så har en rad varianter av L. 
reuteri DSM 17938 med ökad förmåga att tåla stress och binda till slemhinnor 
tagits fram, men för att bättre förstå hur de förbättrade egenskaperna påverkar 
den probiotiska effekten krävs ytterligare utvärdering i mer avancerade modeller 
samt i kliniska studier. De framtagna varianterna av DSM 17938 kan även vara 
till god hjälp för att bättre förstå vad som krävs av en bakterie för att ha en bra 
effekt på hälsan. 
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